

**UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF PENNSYLVANIA**

IN RE: NATIONAL FOOTBALL LEAGUE
PLAYERS' CONCUSSION INJURY
LITIGATION

No. 2:12-md-02323-AB
MDL No. 2323

Kevin Turner and Shawn Wooden,
*on behalf of themselves and
others similarly situated,*

Civil Action No. 2:14-cv-00029-AB

Plaintiffs,

v.

National Football League and
NFL Properties, LLC,
successor-in-interest to
NFL Properties, Inc.,

Defendants.

THIS DOCUMENT RELATES TO:
ALL ACTIONS

DECLARATION OF THOMAS WISNIEWSKI MD

Dr. Thomas Wisniewski affirms under penalty of perjury the truth of the following facts:

1. I am a Professor of Neurology, Pathology and Psychiatry at New York University School of Medicine. I am Director of the following Programs/Centers at NYU: the Center for Cognitive Neurology, the Conformational Disorders Laboratory, the Division of Cognitive Neurology in the Department of Neurology, the Neuropathology Fellowship program, and the Pearl Barlow Memory Disorders Center. I am also co-Director of the NIH funded NYU Alzheimer's Disease Center. My *curriculum vitae* is attached as Exhibit A.

2. I have been asked to submit this declaration in support of the objection to the proposed class action settlement in the above captioned case filed by the MoloLamken LLP law firm. I am not being compensated for my work in doing so.

3. Chronic traumatic encephalopathy (or CTE) is a unique neurodegenerative disease; it is not the same as ALS, Alzheimer's disease, or Parkinson's disease.

4. Repetitive brain trauma is a necessary condition for developing CTE.

5. ALS, Alzheimer's disease, and Parkinson's disease are found in the general population of individuals who have not suffered repetitive brain trauma. Suicidality does not present as a symptom of these diseases.

6. Mood and behavioral impairments such as depression, suicidality, hopelessness, impulsivity, explosiveness, rage, and aggression, although present in the general population, appear more frequently in individuals suffering from CTE than in the general population.

7. The mood and behavioral impairments associated with CTE can present prior to the onset of CTE-related dementia and can be the cause of significant disability and distress for the patient.

8. Based on my experience and knowledge of the clinical and scientific literature, I believe that a reliable, valid, and clinically accepted diagnosis of CTE, based, in part, on objective biomarkers, will likely be possible in the next decade, if not sooner, and long before the 65-year term of the proposed NFL Concussion Litigation Settlement expires.

9. I am not aware of the use of the diagnostic or classification categories of "Neurocognitive Impairment Level 1.0," "Neurocognitive Impairment Level 1.5," or "Neurocognitive Impairment Level 2.0" anywhere in the medical or scientific community.

Pursuant to 28 U.S.C. § 1746, I state under penalty of perjury that the foregoing is true and correct.

Dated: November 25th, 2014

A handwritten signature in dark ink, appearing to read "Thomas J. Wisniewski", is written over a light blue horizontal line.

Thomas Wisniewski MD

Exhibit A

11/26/2014

CURRICULUM VITAE
THOMAS WISNIEWSKI

Current Appointment and Address: Professor of Neurology, Pathology and Psychiatry
New York University School of Medicine
Alexandria East River Science Park, Rm 802
450 East 29th Street
New York, N.Y., 10016

Telephone Number: 212-263-7993

Fax: 212-263-7528

e-mail: thomas.wisniewski@nyumc.org

Web Site: <http://www.med.nyu.edu/biosketch/wisnit01#>

Place of birth: Gdansk, Poland

Citizenship: USA

Education:

1980 BS	University of London, King's College, London, England
1983 MBBS (MD)	King's College Medical School, London, England

Postdoctoral Training:

Internships and Residencies:

1983-1984	Rotating internship in Medicine and Surgery at King's College and West Hill Hospitals, London, England
1984-1985	Resident in Anatomical Pathology, Downstate Medical Center, Brooklyn, New York
1985-1987	Resident of Neurology, New York University Medical Center, New York
1987-1988	Chief Resident of Neurology, New York University Medical Center, New York
1988-1989	Clinical Fellow in Neuropathology, Columbia-Presbyterian Medical Center, Columbia University, New York
1989-1990	Chief Resident of Neuropathology, Columbia-Presbyterian Medical Center, Columbia University, New York

Licensure and Certification:

1984	Certificate of Full Registration as a Medical Practitioner, England
1985	New York State License Registration
1989	American Board of Psychiatry and Neurology Certificate in Neurology
1990	American Board of Pathology Certificate in Neuropathology

Academic Appointments:

11/26/2014

Thomas Wisniewski MD

1987-1988	Assistant Clinical Instructor in Neurology, New York University
1988-1990	Clinical Fellow in Neuropathology, Columbia University, New York
1990-1992	Clinical Instructor in Neurology, New York University
1992-1998	Assistant Professor of Neurology and Pathology, New York University
1997-1998-1999	Director of the Conformational Disorders Laboratory, NYU Associate Professor of Neurology and Pathology, New York University
2000-	Research Scientist, NYS Institute for Basic Research in Developmental Disabilities, Department of Developmental Neurobiology
2002-	Director of the Neuropathology Core of the New York University Alzheimer's Disease Center
1999-2005	Associate Professor of Neurology, Pathology and Psychiatry (tenured), New York University
2005-	Professor of Neurology, Pathology and Psychiatry (tenured), New York University

Hospital Appointments:

1990-1993	Instructor in Neurology, Bellevue Hospital, New York
1993-1998	Assistant Attending in Neurology, Bellevue Hospital, New York
1998-present	Associate Attending in Neurology, Bellevue Hospital, New York
1990-present	Staff Neurologist Manhattan Veterans Administration Hospital, New York
2000-present	Director of the Conformational Disorders Laboratory
2002-present	Director of the Neuropathology Core of the NIH-funded NYU Alzheimer's Disease (AD) clinical center.
2006-present	Director of the Neuropathology Fellowship Program
2007-2009	Member of the NYU Faculty Council
2007-2010	Acting Director of the Pearl Barlow Center for Memory Evaluation and Treatment
2003-present	Director of the Memory and Dementia Disorders Center
2010-present	Chief of the Division of Aging and Dementia, Department of Neurology
2011-present	Associate Director of Research, Comprehensive Center on Brain Aging
2012-2015	Member of the NYU Medical Center Faculty Council
2013-2016	Member of the NYU Senate Council
2013-present	Associate Chair of Research, Department of Neurology
2014-present	Co-Director of the NYU Alzheimer's Disease Clinical Center
2014-present	Director of the NYULMC Center for Cognitive Neurology

11/26/2014

Thomas Wisniewski MD

Major Committee Assignments:

National and Regional:

1992-present	Ad Hoc Committee of Reviewers, Annals of Neurology
1992-present	Ad Hoc Committee of Reviewers, American Journal of Pathology
1995	Program Committee for the American Association of Neuropathology
1995-96	Ad Hoc Neurological Sciences-1 Study Section Committee Member, NIH
1996	Neuroscience of Aging Study Section Committee Member, NIH
1997	Ad Hoc NIH Program Project Study Section Review Committee Member
1998	NIH side-visit of Program Project, University of Southern Alabama
1998	NIH reverse side-visit of Prusiner Program Project, University of California
1998-9	NIH Cellular and Molecular Developmental Neurosciences-2 Ad Hoc Study Section Committee Member
1999-2003	NIH Brain Disorders and Clinical Neurosciences-4 (BDCN-4) Ad hoc study section member.
1999-present	Reviewer for the American Federation of Aging Research
2003	Reviewer for the Department of Defense National Prion Research Initiative
2003-2012	Ad Hoc Study Section Committee Member, National Institutes of Health, BDCN-4 (now known as Clinical Neuroimmunology and Brain Tumors; CNBT 01, SRA: Jay Joshi), meeting at least twice a year from 2003 to 2012
2005- 2009	Permanent Study Section committee member, National Institutes of Health, NIA-N (Neuroscience of Aging) Study Section, term of committee membership: July 1, 2005 to June 30, 2009
2007-2008	Member of the Scientific Program Committee of the 11th International Conference on Alzheimer's Disease and Related Disorders
2010	Member of the NIH Brain Disorders and Clinical Neurosciences (BDCN)-Y(04) study section
2010	Member of the special emphasis panel NIH Brain Disorders and Clinical Neurosciences (BDCN)-T(02) study section
2010-2012	Council member of grant reviewers for the Creutzfeldt-Jakob Disease Foundation Inc.
2011	Member of the special emphasis panel NIH 2011/05 ZRG1 BDCN-Y (02) F meeting; Neurodegenerative Disorders (SRA: Alexander Yakovlev)
2011	Member of the NIH special emphasis panel ZRG1 BDCN-J (02)

11/26/2014

Thomas Wisniewski MD

	M, Neurodevelopment, Neurodegeneration and Stroke (SRA: Jay Joshi)
2011	Member of the NIH special emphasis panel ZRG1 BDCN-C (02) M, Neurodegeneration, Trauma, Immunology and Aging (SRA: Julius Cinque)
2011	Member of the NIH special emphasis panel ZRG1 IDM-V (02) M, Member Conflict: Topics In Microbial Pathogenesis (SRA: Gagan Pandya)
Sept 2012	Member of the NIH special emphasis panel NIH Special Emphasis Panel ZRG1 IDM-B (04), (SRA: Richard Kostriken)
Oct 2012	Member of the NIH special emphasis panel MDCN Integrated Review Group ZRG1 MDCN-F(59) R (SRA: Joanne Fujii)
Feb 2013	Member of NIH special emphasis panel 2013/05 ZRG1 IDM-S (02) M, Member Conflict: Topics in Infectious Diseases and Microbiology (SRA: Liangbiao Zheng)
Feb 2013	Member of NIH 2013/05 CNN Clinical Neuroscience and Neurodegeneration Study Section, (SRA: Samuel Edwards)
June 2013	Member of the NIH special emphasis panel: Neurodegenerative and Neurodevelopmental Disorders Special Emphasis Panel ZRG1 BDCN-Y (02) (SRA: Alexander Yakovlev)
May 2013	Member of the NIH study section: 2013/10 BNVT Bioengineering of Neuroscience, Vision and Low Vision Technologies Study Section (SRA: Robert Elliot)
June 2013	Member of the special NIH/NIA special emphasis panel to review R01 applications in response to RFA AG13-013 (SRA: Alexander Parsadanian)
June 2013	Member of the 2013/10 ZAG1 ZIJ-7 (01) Degenerative and Dementing Diseases study section (SRA: Ramesh Vemuri)
June 2013	Member of the 2013/10 ZRG1 BDCN-Y (02) Neurodegenerative and Neurodevelopmental Disorders Study Section (SRA: Alexander Yakovlev)
Sept 2013	Member of the BDCN Integrated Review Group (BDCN IRG) Grant overview study section (SRA: Joy Joshi)
Sept 2013	Member of the Chronic Dysfunction and Integrative Neurodegeneration (CDIN) Study Section (SRA: Wei-Qin Zhao)
Feb 2014	Member of the Special Emphasis Panel/Scientific Review Group Biobehavioral Regulation, Learning and Ethology (BRLE), 2014/05 ZRG1 BBBP-V (55) R (SRA: Mark Lindner)
March 2014	Chairman and member of the Clinical Neuroimmunology and Brain Tumors Study Section [CNBT] Special Emphasis Panel (BDCN-J (02) M) (SRA: Jay Joshi)
March 2014	Member of the Special Emphasis Panel/Scientific Review Group

11/26/2014

Thomas Wisniewski MD

	2014/05 ZAG1 ZIJ-6 (M1) Drug Development for Alzheimer's Disease (SRA: Alexander Parsadanian)
June 2014	Member of the 2014/10 NSD-C Neurological Sciences and Disorders C Study section. (SRA: William Benzing)
Sept 2014	Member of the U01 AD Drug Development Review Panel ZAG1 ZIJ-6(J4). (SRA: Alexander Parsadanian)

NIH Alzheimer's Disease Research Center and Program Project Site-Visit Committee Member :

Nov., 1993	NIH reviewer of Massachusetts Alzheimer's Disease Research Center
Feb., 1994	NIH reviewer of the University of Southern California Alzheimer's Research Center
Sept., 1994	NIH reviewer of the University of Washington, St. Louis Alzheimer's Disease Research Center
Jan., 1996	NIH reverse site-visit of Alzheimer's Disease Research Centers
March, 1999	NIH site-visit reviewer of Alzheimer's Program Project at USC
Feb, 2000	NIH site-visit reviewer of Program Project at the Univ. of S. Alabama
March, 2000	NIH site-visit reviewer of Program Project at Univ. Cal, Irvine
Oct. 2000	NIH site visit reviewer of Program Project at Univ. Cal, Irvine
Jan, 2001	Member of NIA ADCC grant applications (ZAG1 PCR-5) study section
April 2003	Member of the NIH Review Committee for the Mt. Sinai Medical Center Alzheimer's Disease Research Center
March, 2004	Member of the NIH Review Committee for the Mt. Sinai Medical Center Alzheimer's Disease Program Project
March, 2004	Member of the NIH Review Committee for the John Hopkins University Alzheimer's Disease Program Project
June, 2004	Member of the NIH Review Committee for the University of Philadelphia Program Project (PI Virginia Lee, P01 AG017586-06, Frontotemporal Dementias: Genotypes and Phenotypes).
Jan 2008	Member of the NIH Review Committee for the University of California, San Francisco Program Project (PI Lennart Mucke P01 AG022074-06, Proteinopathies of the Aging Central Nervous System).
Dec 2008	Member of the NIH Review Committee for the University of California, San Francisco Program Project (PI Stanley Prusiner, P01 AG021601-06, Novel Therapeutics for Prion Disease).
2004-present	Member of External Advisor Panel for the Mt. Sinai Alzheimer's Disease Research Center, meeting once a year
2005-present	Member of the External Advisor Panel for the University of South

11/26/2014

Thomas Wisniewski MD

Oct 2009	Florida Alzheimer's Disease Research Center, meeting once a year Member of the NIH Review Committee for the University of California, San Francisco Program Project (PI Stanley Prusiner, P01 AG010770, Pathogenesis of Age-Dependent CNS Degeneration).
Nov 2009	Member of the NIH Review Committee for the University of Pittsburgh School of Medicine Program Project (PI William Klunk, P01 AG025204-06, Neuroimaging and Aging).
June 2010	Member of the NIH Review Committee for the University of California, San Francisco Program Project (PI Stanley Prusiner, P01 AG010770-18, Pathogenesis of Age-Dependent CNS Degeneration).
July 2010	Member of the NIH Review Committee of the University of Philadelphia University Program Project (PI Virginia Lee, P01 AG017586-11, Frontotemporal Dementias, Genotypes and Phenotypes).
October 2010	Member of the NIH Review Committee of the Mount Sinai School of Medicine Program Project (PI Samuel Gandy, P01 AG010491, Interdisciplinary Approach to Alzheimer Drug Discovery).
April 2012	Member of the special emphasis panel ZNS SRB-J (1) "Udall Center Review" (SRA: Birgit Neuhuber)
Nov 2012	Chairman of the of the special emphasis panel to review the UC Irvine Program Project Grant PO1AG000538-34 (PI Carl W Cotman; Behavioral and Neural Plasticity in the Aged)
April 2013	Member of the special emphasis panel: ZNS SRB-J (1) "Udall Center Review" (SRA: Birgit Neuhuber)
Oct 2013	Member of the Alzheimer's Disease Research Center (ADRC) 2014/01 ZAG1 ZIJ-4 (J1) review committee (SRA: William Cruce)
Nov 2013	Member of the special emphasis panel: 2014/01 ZAG1 ZIJ-6 (J2) of the program project grant entitled: Therapeutics for Prion Disease (P.I.: Stanley Prusiner) (SRA: Alexander Parsadanian)
Dec 2013	Chairman of the special emphasis panel: 2014/01 ZAG1 ZIJ-6 (J1) of the program project grant entitled: Behavioral and Neural Plasticity in Aging (P.I.: Carl Cotman) (SRA: Alexander Parsadanian)
April 2014	Member of the special emphasis panel: 2014/05 ZAI1 RWM-M (M1) 1, "NIAID Investigator Initiated Program Project Applications (P01)" (SRA: Richard Morris)
June 2014	Member of the special emphasis panel: 2014/10 ZAG1 ZIJ-5 (O1) Amyloid and Vascular Pathology in AD, 2 P01 AG025204-11

11/26/2014

Thomas Wisniewski MD

June 2014 (P.I.: William E. Klunk) (SRA: Elaine Lewis)
 Member of the special emphasis panel: 2014/10 ZAG1 ZIJ-7 (O1)
 Review of program project entitled: Degenerative and Dementing
 Diseases, PO1AG002132-34 (P.I.: Stanley Prusiner) (SRA:
 Ramesh Vemuri)

June 2014 Chairman of the special emphasis panel: 2014/08 ZAI1 RWM-M
 (S3) 1 "NIAID Investigator Initiated Program Project Applications
 (P01)" for review of PO1 AI106705-01A1 entitled: Mechanisms
 of Transmissibility in Prion Diseases (P.I.: Witold Surewicz)
 (SRA: Richard Morris)

July 2014 Chairman of the special emphasis panel: 2014/08 ZAI1 RWM-M
 (S2) 1 "NIAID Investigator Initiated Program Project Applications
 (P01)" for review of PO1 AI07774-06 entitled: Pathogenesis,
 Transmission and Detection of Zoonotic prion diseases (P.I.:
 Claudio Soto) (SRA: Richard Morris)

Awards:

1999 Zenith Award from the Alzheimer's Disease Association
 2002 Alzheimer Award from *The Journal of Alzheimer's Disease* (for the best
 publication in their Journal for the year).
 2009 Prion 2009 prize at the International Prion 2009 meeting in Greece
 2011 Dr. Henry & Krystyna Wisniewski Memorial Award from the Alzheimer's
 Disease Foundation of Staten Island
 2008-2014 Listed in "Best Doctors in America" (bestdoctors.com)
 2014- Elected as Distinguished Fellow of the Kosciuszko Foundation Collegium
 of Eminent Scientists

Membership in Professional Societies:

1982- British Medical Association
 1984- American Medical Association
 1987- American Academy of Neurology
 1989- American Association of Neuropathology
 1996- Society for Neuroscience
 1998- The Harvey Society
 2012- Fellow of the American Neurological Association

Editorial Boards:

1997-2002 Editorial Board, Amyloid
 1998-2001 Editorial Board, Journal of Neuropathology and Experimental Neurology
 2000-2001 Editorial Board, Journal of Alzheimer's Disease
 2001-2002 Senior Editor, Journal of Alzheimer's Disease
 2002-2005 Editorial Board Acta Neuropathologica

11/26/2014

Thomas Wisniewski MD

2004-2006	Associate Editor Current Alzheimer Research
2008-	Editorial Board Future Neurology
2009-	Editorial Board, Alzheimer's Research and Therapy
2010-2012	Editorial Board, Translational Neuroscience
2011-2013	Editorial Board, Journal of Biological Medicine
2011-2015	Editorial Board, World Journal of Pharmacology
2011-2012	Associate Editor, Journal of Alzheimer's Disease
2011-2014	Editorial Board, PLoS ONE
2011-2015	Senior Foreign Editor, Chinese Journal of Contemporary Neurology and Neurosurgery (ISSN 1672-6731)
2013-2014	Editorial Board, Dataset Papers in Science
2013-2016	Editorial Board, Annals of Vaccines and Immunization

Major Research Interests:

1. The pathogenesis and treatment of Alzheimer's Disease.
2. Treatment approaches for prion diseases.
3. Development of novel amyloid imaging methods.
4. The biochemistry and molecular biology of other cerebral amyloidoses.
5. The neuropathology and etiology of autism and autism spectrum disorders.

Principal Clinical and Hospital Service Responsibilities:

1990-present	Attending Physician, Bellevue Hospital, New York (serve as the Neurology Attending on the general Neurology Ward 1-2 months/year)
1990-present	Attending Physician Neurology Department, Tisch Hospital (NYU Med. Cent.)
1990-present	Neurology Consult Attending Physician, Manhattan Veterans Administration Hospital, New York (serve as the Consult Neurology Attending for general Neurology on a part time basis year round and run a Dementia clinic once/week).
2005-present	Director of Memory and Dementia Disorders Center, NYU Medical Center
2005-present	Member of the Neurology Department Promotions Committee
2006-present	Neuropathology Fellowship Program Director, NYU Medical Center
2008-2010	Acting Director of the Pearl Barlow Center for Memory Evaluation and Treatment, NYUSM
2009-present	Director of the Cognitive Neurology Division of the Department of Neurology, NYUSM
2011-present	Associate Director of Research, NYU Comprehensive Center on Brain

11/26/2014

Thomas Wisniewski MD

Aging

- 2013-present Associate Chair for Research, NYU Department of Neurology
- 2014-present Co-Director of the NYU NIH funded Alzheimer's Disease Clinical Core
- 2014-present Director of the NYU Center for Cognitive Neurology

Teaching Experience:

- 1984-1985 Organized lectures in General Pathology, Downstate Medical Center, Brooklyn, New York
- 1987-1988 Lecture Organizer in General Neurology, New York University Medical Center
- 1988-1990 Course developer and lecturer in Neuropathology, Columbia-Presbyterian Medical Center, New York
- 1990-present Clinical Lecturer in Neurology Course, New York University Sch. Med.
- 1998-present Lecturer and Organizer of Mechanisms of Disease: The Nervous System Course, NYU Sch. Med.
- 1999-present Lecturer in Molecular Signaling and Drug Development Course, NYU Sch. Med.
- 1999-present Lecturer in Neurogenetics Course, NYU Sch. Med.
- 1999-present Lecturer in Pathology Board Review course (Neuropathology), NYU Sch. Med.
- 2000-2005 Lecturer in Psychiatry Board Review course, NYU Sch. Med.
- 2008-present Lecturer in the Advanced Immunology: Neuroimmunology Course, NYU Sch. Med.
- 2009-present Lecturer in Neuroscience Course in Disorders, NYU Sch. Med.
- 2006-present Director of Neuropathology Fellowship, NYU Sch. Med.
- 2012 Lecturer and Course designer of the first Interclerkship Intensive for NYULMC Class of 2014 on Cognitive Issues in the Health Care Setting: Informed Consent, Physician Impairment, Capacity, Ethics, Dementia and Delirium.

Clinical Trial Participation:

- 2011-2012 Investigator on protocol ELN115727, a Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Alzheimer's Disease who Participated in Study ELN115727-301 or in Study ELN115727-302 (Protocol ELN115727-351), sponsor: Janssen Ltd.
- 2011-2013 Safety Monitor of Study: Family History of Alzheimer's Disease (AD), Hypometabolism and Oxidative Stress , Protocol: H# 08-857
- 2011-2012 Investigator on Protocol H8A-MC-LZAM, Effect of Solanezumab (LY2062430), an Anti-amyloid beta monoclonal antibody on the

11/26/2014

Thomas Wisniewski MD

- progression of Alzheimer's disease as compared to placebo; sponsor: Eli Lilly and Co.
- 2013-2014 Investigator on protocol BP28248, RO460522 Efficacy and Safety Study in Moderate AD; sponsor: Roche/Genentech
- 2013-2014 Investigator on protocol 017 P07738, A randomized, placebo controlled, parallel-group, double blind efficacy and safety trial of MK-8931 in subjects with mild to moderate Alzheimer's disease; sponsor: F.Hoffmann-La Roche Ltd
- 2014-2015 Investigator on protocol S12-01284, Phase II study to evaluate the impact on biomarkers of resveratrol treatment in patients with mild to moderate Alzheimer's disease; sponsor: NIH
- 2014-2015 Investigator on protocol S14-00053, Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD); sponsor: Merck Sharp & Dohme
- 2014-2015 Investigator on protocol S14-00148, A Phase 2, randomized, multicenter, double blind, placebo controlled, parallel group study comparing HT-0712 with placebo in subjects with age associated memory impairment (AAMI); sponsor: Dart NeuroScience

Grant Support:**Principal Investigator:**

- 1991-1994 PI of Alzheimer's Disease Association, Clinical Investigator Initiated Award Grant (IIRG91-102): The Lewy body Variant of Alzheimer's disease
- 1992-1997 PI of National Institute of Health (National Institute of Aging) Clinical Investigator Award (K08-AG00542-01): Lewy Body Disease and Gelsolin
- 1992-1993 PI of New York University Medical Center Alzheimer's Disease Center Pilot Study: The Source of Alzheimer's Amyloid Protein.
- 1995-1996 PI of New York University Medical Center Alzheimer's Disease Center Pilot Study: Alzheimer's disease and Amyloid β Fibrillogenesis.
- 1995-1996 PI of National Institute of Health (National Institute of Aging) Pilot Study in LEAD award. Theoretical molecular modeling of amyloid β .
- 1997-1998 PI of National Center for Research Resources, National Institute of Health. Shared Instrumentation Grant. FTS-6000 Spectrometer Mainframe
- 1997-1998 PI of National Institute of Health (National Institute of Aging) Pilot Study in LEAD award (AG10953) The Biochemistry of Human Prion Strains.
- 1998-2001 PI of Alzheimer's Disease Association, Investigator Initiated Award:

11/26/2014

Thomas Wisniewski MD

Imaging of Alzheimer's disease lesions *in vivo* (IIRG-98-017)

1999-2001 PI of Alzheimer's Disease Association, Zenith Award: Amyloid β and Apolipoprotein E Interactions in Vivo and *in Vitro* (Zenith-99-1791).

2000-2005 PI of the Neuropathology Core on NIH Program Project (PO1AG17617): In Vivo Models of Neuronal and Vascular Pathobiology in AD (PI of Program Project is Dr. Ralph Nixon)

2000-2004 PI of Project 3 (The role of ischemia and vascular pathology in Alzheimer's disease) on NIH Program Project (PO1AG17617): In Vivo Models of Neuronal and Vascular Pathobiology in AD

2000-2002 PI of American Parkinson Disease Association Investigator Grant: Biochemistry and Immunohistochemistry of Lewy Bodies.

2002-2005 PI of Alzheimer's Disease Association, Investigator Initiated Research Award: Vaccine Therapy for the Prevention and Treatment of Prion Disease (IIRG-02-3702), Annual Direct: \$72,727

2006-2009 PI of Alzheimer's Disease Association, Investigator Initiated Research Award: Mucosal Immunization Therapy in Alzheimer's Disease Mice (IIRG-06-26434), Annual Direct: \$72,727

2005-2008 PI of NIH Fogarty International Research Collaborative Award, (R03 TW006848): Therapy for Alzheimer and Prion diseases. Annual Direct: \$30,342

2007-2009 PI of NIH/NIA/Fogarty International Center R21 grant (R21 AG028187) Immunization Approaches for Alzheimer's Disease. Annual Direct: \$86,700

2000-2015 Director of the Neuropathology Core of the NYU Alzheimer's Disease Clinical Center (NIH NIA AG08051), Annual Direct: \$100,000

2008-2014 PI of Neuropathology Core of PPG "Characterization of the Pathological and Biochemical Markers that Correlate to the Clinical Features of Autism", AS073234; US Army Medical Research Acquisition Act (W81XWH-08-1-0741), Annual Direct of Core: \$123,404; total project \$1,900,000

1999-2011 PI of National Institute of Health (NIA) R01 Amyloid β peptide and apolipoprotein E AG15408, Annual Direct: \$ 173,939

2002-2012 PI of NIA/NIH R01 grant: Detection and Clearance of AD Amyloid Lesions. AG20245, Annual Direct: \$184,500

2004-2014 PI of NINDS/NIH R01 grant: Therapeutic Approaches for Prion Disease, NS047433; Annual Direct: \$250,000

2009-2013 PI of Challenge Grant 3R01NS047433-06S1 NIH/NINDS; Therapeutic Approaches for Prion diseases. Total Direct Costs for Grant: 1,242,287.00

2010-2013 PI of Alzheimer's Association Investigator Initiated Research Grant: Immunotherapy for amyloid plaques, CAA and NFT pathology. Total Direct Costs for the Grant: \$200,000

2010-2015 PI of NINDS/NIH R01 grant: 1R01NS073502: Therapeutic Targeting of

11/26/2014

Thomas Wisniewski MD

Abnormal Conformation in Neurodegenerative Disease. Annual Direct: \$218,750

2011-2012 NYU Langone Multiple R01 Research Incentive Grant, Annual Direct: \$20,000.

2013-2015 PI of Seix Dow Foundation Grant, Annual Direct: \$1,000,000

2012-2013 PI of an Alzheimer's Drug Discovery Foundation grant: Development of peptidomimetic ApoE/A β Binding Inhibitors as an Effective and Non-toxic Therapeutic Approach for AD, Annual Direct: \$100,000

2012-2013 NYU Langone Multiple R01 Research Incentive Grant, Annual Direct: \$24,425.

2012-2017 PI of NIA/NIH R01 grant: Detection and Clearance of AD Lesions. AG20245, Annual Direct: \$200,000.

2014-2019 PI of NIAID/NIH R01 grant: Vaccination for Chronic Wasting Disease. AI108213-01A1, Annual Direct: \$759,860. Under review

Co- Investigator/Co-PI:

1995-1999 Co-Investigator of National Institute of Health (National Institute of Aging) (R01 AG08721-04, PI: Frangione, B): Amyloid Angiopathy, Early Plaque and Aging

1999-2004 Co-Investigator of National Institute of Health (R01 AR02594, PI: Frangione B): Conformational Disorders: Amyloid and Prion Proteins. Annual Direct: \$250,000

2009-2011 Co-Investigator National Institute of Health (1RC2AG036501-0110, PI: de Leon M): Imaging Neuroinflammation in Alzheimer's Disease with [11C]Arachidonic Acid.

2011-2012 Co-PI of NYU Applied Research Support Grant (Co-PI: Goni F) Monoclonal Antibody Development Targeting Pathological Oligomers as a Treatment for Alzheimer's Disease. Annual Direct: \$50,000

2012-2014 Co-PI of NIH 1R21NS079676-01 (PI: Henrieta Scholtzova): Testing of Innate Immunity Stimulation via TLR9 on CAA using Non-human Primates. Annual Direct: \$150,000

2014-2016 Co-PI of SBIR NIH grant 1R43AG044248-01 (PI: Andrew Wang): Detection of Vascular and Plaque Alzheimer's Amyloid Deposits by microMRI using Iron Oxide Nanoparticles, under review. Company partner: Ocean NanoTech, LLC. Annual Direct: \$150,000, under review

2012-2016 Co-PI of a Research Training Grant from the Saudi Arabia Cultural Mission to Train Saudi Physicians in Neuroscience Research (PI: Allal Boutajangout/Wisniewski). Annual Direct: \$320,000

2012-2015 Co-PI of Alzheimer's Disease Association Investigator Initiated Grant

11/26/2014

Thomas Wisniewski MD

	IIRG-12-239474 (PI: Henrieta Scholtzova): Innate immunity stimulation as a novel therapeutic approach in AD. Annual Direct: \$80,000
2013-2016	Co-PI of Alzheimer's Disease Association Investigator Initiated Grant IIRG-13-283707 (PI: Fernando Goni): Conformational Directed Immunotherapy Targeting both Tau and A β Pathology. Annual Direct: \$80,000, Annual Direct: \$80,000
2014-2016	Investigator on NIH grant: Restoring Animal Research Resources Lost Due to Super Storm Sandy. 1R24OD018339-01 (PI: David Levy) Direct Costs: \$3,971,911. Budget to Wisniewski Lab: \$59,211/yr
2014-2019	Mentor on NIH Grant (K23 AG048622-01): New Region-Specific Targeted MRI to Characterize Alzheimer's Disease Pathology (PI: T. Shepherd). Direct Costs: \$178,630/yr.

Patents:

11/26/2014

Thomas Wisniewski MD

- 1) Synthetic Immunogenic but Non-Amyloidogenic Peptides Homologous to Amyloid β for Induction of an Immune Response to Amyloid β and Amyloid Deposits; **Wisniewski T**, Frangione B, Sigurdsson E. Filed 5/22/2001, **Granted: 3/30/2004**, **Patent Number: 6,713,450**
- 2) Detection of Alzheimer's Amyloid by Magnetic Resonance Imaging; **Wisniewski T**, Sigurdsson, E, Zaim Y, Turnbull D. Filed 5/23/2001, **Granted: 11/23/2004**, **Patent Number: 6,821,504**
- 3) Synthetic Immuogenic but Non-Deposit-Forming Polypeptides and Peptides Homologous to Amyloid β , Prion Protein, Amylin, α -Synuclein or Polyglutamine Repeats for Induction of an Immune Response Thereto. Frangione B, Sigurdsson E, **Wisniewski T**. Filed 11/21/02, **Granted: 01/20/09**, **Patent Number: 7,479,482**
- 4) Synthetic immunogenic but non amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits. **Wisniewski T.**, Sigurdsson E, Frangione B. Filed 09/19/03, **Granted 09/23/2008**, **Patent Number: 7,427,655**
- 5) Prevention and Treatment of Alzheimer Amyloid Deposition. **Wisniewski T**, Sadowski M, Sigurdsson E, Frangione B . Filed 3/26/04, **Granted: 12/15/09**, **Patent Number: 7,632,816**
- 6) Mucosal Immunization to prevent prion infection. **Wisniewski T**, Sigurdsson E, Chabalgoity JA, Goni F. Filed 11/18/05, Application Number: 20070059807 (NYU: 10/558,276), **Granted by patent office 11/7/13; Issued 04/01/14**, **Patent Number: 8,685,718**
- 7) Imaging Agents for Protein Misfolding. **Wisniewski T**, Min J, Li Q, Chang YT. Filed 2/11/08, Application Number: 20100279340 (NYU: 12/029,271), **Issued 4/17/12: Patent Number: 8,158,380.**
- 8) Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta. for induction of an immune response to amyloid beta and amyloid deposits. Frangione B, **Wisniewski T**, Sigurdsson EM, **Issued 4/20/10: Patent Number: 7,700,107**
- 9) Method for treating amyloid disease. Frangione B, Sigurdsson EM, **Wisniewski T**, Ghiso J. Filed 02/05/09. **Patent Issued: 11/27/12; Patent Number: 8,318,175**
- 10) Immunotherapy targeting the shared abnormal conformational state of amyloidogenic peptides/proteins. **Wisniewski T**, Goni F. Filed 05/05/10; Application No.: 20100284909 (12/774,293), **Issued: 4/2/13; Patent Number: 8,409,584**

11/26/2014

Thomas Wisniewski MD

- 11) Method for treating amyloid disease. Wisniewski T, Goni F. Filed 7/19/12. **Patent Issued: 1/24/13; Patent Number: WO 2013/013056 A1**
US patent (13/553,566) allowed 8/8/14, issue of patent pending payment of issue fee
- 12) Preventing and treating amyloid- β deposition by stimulation of innate immunity. **Wisniewski T**, Scholtzova H, Kasczak RJ, Spinner DS. Filed 08/20/2008, Application Number: 12/918,739, pending
- 13) Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides. **Wisniewski T**, Goni F. Filed 07/19/11; Application No.: 61509320, pending
- 14) A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment. **Wisniewski T**, Zhang W, Dang S. Filed 8/2/12; **Patent Issued: 02/06/14; Patent Number: 20140037629**

Listing (Partial) of Past and Present Students, Trainees and Faculty Members of Conformational Disorders Laboratory (P.I. Thomas Wisniewski):

11/26/2014

Thomas Wisniewski MD

Past / Current Trainee	Trainee Name	Pre or Post Graduate	Post Doc Research Training Period	Prior Academic Degree			Title of Research Project	Present Position (past trainees) Source of Support (Present trainees)
				Degree(s)	Year(s)	Institutions(s)		
Past	Sigurdsson, Einar	Post	1999-2001	Ph.D.	1997	Pharmacology; Loyola University	Multiple projects: Vaccination for conformational disorders	Associate Professor of Physiology and Neuroscience, and Psychiatry, NYUSM
Past	Golabek, Adam	Post	1996-2002	Ph.D.	1996	Polish Academy of Science	Pathological Chaperones and AD	Research Scientist, Grade V, NYU Institute for Basic Research in Developmental Disabilities
Past	Dowjat, Karol	Post	1996-2003	Ph.D.	1992	Polish Academy of Science	The role of presenilin in the pathogenesis of familial AD	Research Scientist, Grade VI, NYU Institute for Basic Research in Developmental Disabilities
Past	Aucouturier, Pierre	Post	1999-2002	Ph.D.	1993	University of Paris, France	Role of Dendritic cells in the infectivity of Prions	Senior Lecturer at Université Pierre et Marie Curie, Paris, France.
Past	Permann, Bruno	Post	1999-2002	Ph.D.	1998	University of Paris, France	The role of apoE in Aβ fibrillogenesis	Research Scientist, Merck-Serono, Geneva, Switzerland
Past	James Ripellino	Post	2003-2004	PhD	1990	Boston University	Amyloid beta measurement in biological fluids	Left academics
Past	Tezapsidis, Nikolas	Post	2000-2001	PhD	1991	The University of Sussex, UK	The role of presenilin in Alzheimer's disease	Assistant Professor, Columbia University

11/26/2014

Thomas Wisniewski MD

Past	Wu, Hope	Post	2003-2004	MD PhD	1982 1992	Shanghai Medical University University of Minnesota	Novel Imaging agents for amyloid lesions	Attending Pathologist, NY Eye and Ear Infirmary
Past	Shao, Charles	Post	2000-2002	MD PhD	1983 1990	Beijing Second Medical College, China Emory University	The role of apoE isotypes in AD	Assistant Professor of Pathology, SUNY Downstate Medical Center
Past	Sadowski, Martin	Post	2002-2009	MD PhD	1995 1996	Medical University of Gdansk, Gdansk, Poland	The role of apolipoprotein E in Alzheimer's disease	Associate Professor of Neurology, NYUMC
Past	Fowkes, Mary	Post	2003-2005	MD	1999	University of Maryland	Neuropathology Fellow	Assistant Professor of Pathology, Mt. Sinai School of Medicine
Past	Boutajangout, Allal	Post	2005-2008	PhD	2005	Free University of Brussels, Belgium	A β Immunomodulation for AD	Res. Assistant Professor, NYUSM;
Present	Li, Yong-sheng	Post	2001-present	MD	1995	Shanghai Medical University	Developing Imaging Agents for AD	NYU Research Scientist, NYUSM NIH AG20245
Present	Scholtzova, Henrieta	Post	2001-present	MD PhD	1999 2010	P.J. Safarik University, Kosice, Slovakia NYU	Innate immunity for AD therapy Immunotherapy for Neurodegenerative disorders	Assistant Professor of Neurology, NYULSM; NIH NS047433 and AG 20245
Present	Prelli, Frances	Post	2003-present	BS	1960	NYU	Models of Prion infection	Associate Scientist, NYUSM; NIH NS047433 Alzheimer's disease Association
Past	Ji, Yong	Post	1998-2002 2008-2010	MD	1995	Shanghai Medical University	In vivo imaging of amyloid lesions	Chairman of Neurology, Tianjin Central Hospital, China

11/26/2014

Thomas Wisniewski MD

Past	Pankiewicz, Joanna	Post	2004-2010	MD PhD	1994-2001	Collegium Medicum Jagiellonian Univ. Cracow, Poland	Therapeutic antibodies for prion disease	Research Assistant Professor of Neurology; NYUMC
Present	Goni, Fernando	Post	2003-Present	PhD	1983	University of Buenos Aires	Vaccination for prion disease	Associate Scientist, NYUSM; NIH NS47433 and AG028187
Present	Sun, Yanjie	Post	2007-Present	MS	1997	China Medical University	Transgenic models of neurodegeneration	Research Scientist, NYUSM, NIH AG 15408
Past	Lilla Hatos-Agyi	Post	2010-11	MD	2008	Medical University of Innsbruck	Vaccination studies on Tg mice	Transplant Coordinator
Past	Yang, Jing	Pre	2006-2011	PhD student	2011	Graduated NYU PhD Sackler program Jan. 2011	μ MRI Detection of amyloid deposits and therapeutic approaches for their clearance by inhibition of apoE/A β interactions in AD	Medical Student
Past	Guihot, Jeanne	Pre	2011	BS PhD Student		2010 Rennes 1 University France	Behavioral Studies in AD model mice	Completing PhD
Past	Shannon Chiu	Post	2011	BA MD student	2008-2014	Williams College NYU School Medicine	μ MRI studies in Tg mice	Neurology Resident Mayo Clinic
Past	Luis Bragarolas	Post	2011	BS PhD student	2011	University of Barcelona	Conformational studies of amyloid proteins	Research Scientist University of Barcelona
Past	Erika Chung	Pre	2006-2011	PhD	2011	NYU PhD Sackler program,	Novel therapeutic approaches for	Laboratory Manager Biotechnology Start up Company

11/26/2014

Thomas Wisniewski MD

						graduated 09/2011	prion diseases	
Past	Sara Ghobraiel	Pre	201-2012	MD	2012	School of Medicine's Honors Program	Detection and Clearance of AD Lesions	Internal Medicine Resident
Past	Sarah Lund	Pre	2012	BS	2012	Summer Undergraduate Research Program in Graduate Biomedical Sciences	Detection and Clearance of AD Lesions	PhD student, Oxford University
Past	Chan Tian	Post	2012	MD PhD	2002-2007	Peking University	Therapeutic Approaches for Prion Diseases	Professor, Peking University
Past	Clare Cunliffe	Post	2005-2008	MD	2000	University of London	Neuropathology Fellow	Pathology Faculty University of Edinburgh
Current	Shan Liu	Post	2011-	PhD	2006	Fudan University	Detection and Clearance of AD Lesions	NIH, AG20245
Past	Kia Newman	Post	2009-2011	MD	2004	University of Miami	Neuropathology Fellow	Medical Examiner OCME NYC
Past	Kant Matsuda	Post	2010-2012	MD	2005	University of Tokyo	Neuropathology Fellow	Assistant Professor of Pathology, University of Manitoba
Past	Valentino Wong	Pre	2011-	BA	2010	Dartmouth College	Therapeutic Targeting of Abnormal Conformation in Neurodegenerative Disease	Medical Student
Past	Ariel Brietbart	Pre	2012-2013	BS	2010	NYU	Detection and Clearance of AD Lesions	Medical Student
Past	Daniel Peyser	Post	2012-2013	BS	2011	NYU	Therapeutic Approaches for Prion Diseases	Medical Student
Current	Krystal	Post	2012-	BS	2011	Augusta State	Therapeutic	NIH, NS47433

11/26/2014

Thomas Wisniewski MD

	Herline					University	Approaches for Prion Diseases	
Past	Eileen Do	Post	2012-2013	BS	2011	NYU	Detection and Clearance of AD Lesions	Medical Student
Past	Shannon Monaghan	Post	2012-2013	BS	2008	University of North Texas	Therapeutic Targeting of Abnormal Conformation in Neurodegenerative Disease	Medical Student
Current	Arline Faustin	Post	2011-2015	MD	2006	SUNY Downstate Medical Center	NYU Alzheimer's Disease Clinical Center	NIH, NIA AG08051
Past	Faris Yaghmour	Post	2012-2014	MBBS	2008	Umm Al Qura University	Neuroscience Training Fellowship	Clinical Instructor Umm Al Qura University
Past	Ahmed Noorsaeed	Post	2013-2014	MBBS	2009	King Bin Abdul-Aziz for Health Sciences	Neuroscience Training Fellowship	Pathology Resident Mt. Sinai School of Medicine
Past	Peter Chianchiano	Pre	2012-2014	BS	2011	NYU	Detection and Clearance of AD Lesions	PhD Student University of Connecticut
Current	Lisa Sprinzen	Pre	2012-2014	BS	2012	NYU	Induction of TLR9 Signaling to Reduce Alzheimer's Pathology in Squirrel Monkeys	NIH, NS073502
Past	Shannon Chiu	Post	2013-14	BS, MD student	2011	Williams College, NYU School Medicine	Innate Immunity Stimulation for AD Treatment	Neurology Resident Mayo Clinic
Past	Madeline Velez	Post	2014	BS, MD student	2008 2014	NYU School Medicine	Identification of novel imaging agents for tau and oligomers	Surgery Resident NYU

11/26/2014

Thomas Wisniewski MD

Current	Mitchell Marta Ariza	Pre	2014- 2015	BSc	2011	Pontificia Universidad Javeriana	Therapeutic Approaches for Prion Diseases/Seix Dow Found.	NIH, NS47433 Seix Dow Foundation
Current	Helen Lyo	Pre	2013- 2014	BA	2015	NYU College of Arts and Sciences	Approaches to stimulate innate immunity in AD	NIH, NS73502 Seix Dow Foundation
Current	Timothy Shepard	Post	2014- 2019	MD	2009	NYU School Medicine	New Region- Specific Targeted MRI to Characterize Alzheimer's Disease Pathology	Assistant Professor of Neurology, NYULMC NIH, K23 AG048622-01
Current	Franck Maurinot	Pre	2014	BA	2013	University of Paris 7	In vitro models of TLR9 stimulation	NIH, AG20245
Current	Shleshm a Dhakal	Pre	2014- 2015	BA	2013	City College of New York- CUNY	Role of Microglia/Macr ophages in AD Pathogenesis	NIH, AG20245, Seix Dow Foundation

11/26/2014

Thomas Wisniewski MD

Bibliography:**Peer Reviewed Original Data Journal Publications (Abstracts are not listed. Reviews, books and book chapters are listed separately)**

1. Moon HM, **Wisniewski T**, Mertz P, DeMartini J, Wisniewski HM. Purification of neurofilament subunits from bovine brains and studies on neurofilament assembly. *Journal of Cell Biology* 1981; 89:560-567.
2. Kitaguchi T, Wisniewski KE, Maslinska S, Maslinska D, **Wisniewski TM**. β -Amyloid immunoreactivity in patients with neuronal ceroid lipofuscinosis: ultrastructural and biochemical demonstration. *Neuroscience Letters* 1990; 112:155-160.
3. Onesti S, **Wisniewski T**, Post K. Clinical versus subclinical pituitary apoplexy: presentation, surgical management and outcome in 21 patients. *Neurosurgery* 1990; 26:980-986.
4. Onesti S, **Wisniewski T**, Post K. Pituitary apoplexy associated with a Rathke's cleft cyst. *Neurosurgery* 1990; 27:644-646.
5. **Wisniewski T**, Sisti M, Inhirami G, Knowles D, Powers J. Solitary intracranial plasmacytoma: immunohistochemical and molecular studies. *Neurosurgery* 1990; 27:826-829.
6. Kitaguchi T, Wisniewski KE, Maslinski S, Maslinska D, **Wisniewski TM**, Kim KS. Beta-protein immunoreactivity in brains of patients with neuronal ceroid lipofuscinosis: ultrastructural and biochemical demonstration. *Neuroscience Letters* 1990, 112:155-160.
7. **Wisniewski T**, Haltia M, Ghiso J, Frangione B. Lewy bodies are immunoreactive with antibodies raised to gelsolin related amyloid. *American Journal of Pathology* 1991; 138:1077-1083.
8. Castano EM, **Wisniewski T**, Frangione B. Inherited amyloids of the nervous system. *Current Opinion in Neurobiology* 1991; 1:448-454.
9. Haltia M, Ghiso J, Miller D, Frangione B, **Wisniewski T**. Gelsolin variant and β -amyloid co-occur in a case of Finnish amyloidosis and Alzheimer's. *Neurobiology of Aging* 1991; 12:313-316.
10. **Wisniewski T**, Ghiso J, Frangione B. Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have

11/26/2014

Thomas Wisniewski MD

accelerated amyloid fibril formation. *Biochemical and Biophysical Research Communications* 1991; 179:1247-1254.

11. Constantinidis J, **Wisniewski TM**. The dominant form of the pigmentary orthochromatic leukodystrophy. *Acta Neuropathologica* 1991; 82:483-487.
12. **Wisniewski T**, Haltia M, Ghiso J, Frangione B. Lewy bodies and gelsolin. *Parkinson/Alzheimer Digest* 1992; 1:6-8.
13. Iwaki T, **Wisniewski T**, Iwaki A, Corbin E, Tomokane N, Tateishi J, Goldman JE. Accumulation of α B-crystallin in central nervous system glia and neurons in pathological conditions. *American Journal of Pathology* 1992; 140:345-356.
14. Ghiso J, **Wisniewski T**, Vidal R, Rostagno A, Frangione B. Epitope mapping of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease. *The Biochemical Journal* 1992; 282:517-522.
15. **Wisniewski T**, Frangione B. Apolipoprotein E: a pathological chaperone in systemic and cerebral amyloidoses. *Neuroscience Letters* 1992; 135:235-238.
16. Constantinidis J, Wisniewski KE, **Wisniewski TM**. Senile neuronal ceroid lipofuscinosis, a report of three cases and a review of the literature. *Acta Neuropathologica* 1992; 83:461-468.
17. **Wisniewski T**, Frangione B. Molecular biology of the Dutch variant of Alzheimer's disease. *Molecular Biology* 1992; 6:75-86.
18. Rodrigues M, Rajagopalan S, Jones K, Nirankari V, **Wisniewski T**, Frangione B, Gorevic P. Gelsolin immunoreactivity in corneal amyloid, macular and granular dystrophies and wound healing. *American Journal of Ophthalmology* 1993; 115:644-652.
19. **Wisniewski T**, Golabek A, Matsubara E, Ghiso J, Frangione B. Apolipoprotein E: binding to soluble β -amyloid. *Biochemical Biophysical Research Communications* 1993; 192:359-365.
20. Ghiso J, Matsubara E, Koudinov A, **Wisniewski T**, Frangione B. Alzheimer's amyloid β specifically binds SP40,40 (Apolipoprotein J), an inhibitor of the complement membrane attack complex. *The Biochemical Journal* 1993; 293:27-30.
21. **Wisniewski T**, Castano E, Ghiso J, Frangione B. Cerebrospinal fluid inhibits fibrillogenesis by Alzheimer's disease peptides. *Annals of Neurology* 1993; 34:

11/26/2014

Thomas Wisniewski MD

631-633.

22. **Wisniewski T**, Ghiso J, Frangione B. Alzheimer's disease and soluble A β . *Neurobiology of Aging* 1994; 15:143-152.
23. **Wisniewski T**, Lalowski M., Levy E., Marques M.R.F., Frangione B. The amino acid sequence of neuritic plaque amyloid from a familial Alzheimer's disease patient. *Annals of Neurology* 1994; 35:245-246.
24. Kida E, Golabek A, **Wisniewski T**, Wisniewski K. Regional differences of Apolipoprotein E immunoreactivity in diffuse plaques in Alzheimer's disease brain. *Neuroscience Letters* 1994; 167: 73-76.
25. Sanan DA, Weisgraber KH, Mahley RW, Huang D, Saunders A, Schmechel D, **Wisniewski T**, Frangione B, Roses A, Strittmatter WJ. Apolipoprotein E associates with β Amyloid peptide of Alzheimer's Disease to form novel monofibrils: Isoform Apo E4 associates more efficiently than Apo E3. *Journal of Clinical Investigation* 1994; 94:860-869.
26. Gallo G, **Wisniewski T**, Choi-Miura N, Ghiso J, Frangione B. Potential role of Apolipoprotein E in fibrillogenesis. *American Journal of Pathology* 1994; 145:1-5.
27. **Wisniewski T**, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. *American Journal of Pathology* 1994; 145:1030-1035.
28. Zlokovic BV, Martel CL, Mackic JB, Matsubara E, **Wisniewski T**, McComb G, Frangione B, Ghiso J. Brain uptake of circulating apolipoprotein J and E complexed to Alzheimer's amyloid β . *Biochemical Biophysical Research Communications* 1994; 205:1431-1437.
29. **Wisniewski T**, Morelli L, Wegiel J, Levy E, Wisniewski HM, Frangione B. The influence of apolipoprotein E isotype on Alzheimer's disease pathology in 40 cases of Down's syndrome. *Annals of Neurology* 1995; 36:137-139.
30. Mangone C, Castano E, Levy E, Abiusi G, **Wisniewski T**, Marques M, Faccio E, Gorelick P, Frangione B, Sica R. Early onset Alzheimer's disease in a South American pedigree. Clinical, SPECT, immunohistochemical and DNA findings. *Acta Neurologica Scandinavica* 1995; 91:6-13.
31. Ghiso J, Plant GT, Revesz T, **Wisniewski T**, Frangione B. Familial cerebral angiopathy

11/26/2014

Thomas Wisniewski MD

(British type) with nonneuritic amyloid plaque formation may be due to a novel amyloid protein. *Journal of Neurological Sciences* 1995; 129: 74-7.

32. Castano EM, Prelli F, **Wisniewski T**, Golabek A, Kumar RA, Soto C, Frangione B. Fibrillogenesis of Alzheimer's Amyloid β peptides and apolipoprotein E. *Biochemical Journal* 1995; 306:599-60.
33. Golabek A, Marques MA, Lalowski M, **Wisniewski T**. Alzheimer's Disease amyloid binding proteins in vitro and in normal human cerebrospinal fluid. *Neuroscience Letters* 1995; 191:79-82.
34. **Wisniewski T**, Golabek AA, Kida E, Wisniewski KE, Frangione B. Conformational mimicry in Alzheimer's disease. *American Journal of Pathology* 1995; 147:238-244.
35. **Wisniewski T**, Lalowski M, Golabek A, Frangione B. Alzheimer's Disease: An apolipoprotein E amyloidosis? *The Lancet* 1995; 345: 956-958.
36. **Wisniewski T**, Frangione B. Amyloidosis in Alzheimer's disease. *The Lancet* 1995; 346: 441.
37. **Wisniewski T**, Palha JA, Ghiso J, Frangione B. S182 protein in Alzheimer's disease neuritic plaques. *The Lancet*, 1995 346:1366.
38. **Wisniewski T**, Lalowski M, Bobik M, Russell M, Strosznajder J, Frangione B. Amyloid β 1-42 deposits do not lead to Alzheimer's neuritic plaques in aged dogs. *Biochemical Journal* 1996; 313: 575-580.
39. **Article Featured on Cover:** Vidal R, Garzuly F, Budka H, Lalowski M, Linke RP, Brittig F, Frangione B, **Wisniewski T**. Meningovascular amyloidosis associated with a novel transthyretin (TTR) missense mutation at codon 18 (TTRD18G). *American Journal of Pathology* 1996;148: 361-366.
40. **Wisniewski T**, Lalowski M, Baumann M, Rauvala H, Raulo E, Nolo R, Frangione B. HB-GAM is a cytokine present in Alzheimer's and Down's Syndrome Lesions. *Neuroreport* 1996; 7: 667-671.
41. Baumann MH, **Wisniewski T**, Plant GT, Levy E, Ghiso J. Identification of C-terminal fragments of α - and β -tubulin in amyloid deposits of the familial cerebral amyloid angiopathy, British type. *BiochemicalBiophysical Research Communications* 1996; 219: 238-242.
42. Baumann MH, Golabek A, Lalowski, **Wisniewski T**. Micropreparative gel

11/26/2014

Thomas Wisniewski MD

- electrophoresis of small molecular weight peptides: purification of highly insoluble amyloid peptide fragments. *Analytical Biochemistry* 1996, 236: 191-198.
43. Soto C, Golabek A, **Wisniewski T**, Castano EM. Alzheimer's soluble β -amyloid is conformationally modified by apolipoprotein E in vitro. *Neuroreport* 1996, 7: 721-725.
 44. Palha JA, Moreira P, **Wisniewski T**, Frangione B, Sariaiva MJ. Transthyretin gene in Alzheimer's disease patients. *Neuroscience Letters* 1996; 204: 212-214.
 45. Golabek A, Soto C, Vogel T, **Wisniewski T**. The interaction between apolipoprotein E and Alzheimer's amyloid β -peptide is dependent on β -peptide conformation. *The Journal of Biological Chemistry* 1996; 271: 10602-10606.
 46. Lemere CA, Blusztajn JK, Yamaguchi H, **Wisniewski T**, Saido T, Selkoe D. Sequence of deposition of heterogeneous amyloid β -peptides and apo E in Down syndrome: implications for initial events in amyloid plaque formation. *Neurobiology of Disease* 1996; 3:16-32.
 47. Vidal R, Ghiso J, **Wisniewski T**, Frangione B. Alzheimer's presenilin 1 gene expression in platelets and megakaryocytes: Identification of a novel splice variant. *FEBS Letters* 1996; 393: 19-23.
 48. Garzuly F, **Wisniewski T**, Brittig F, Budka H. Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly). *Neurology*, 47: 1562-1567, 1996.
 49. Lalowski M, Golabek A, Lemere CA, Selkoe DJ, Wisniewski HM, Beavis RC, Frangione B, **Wisniewski T**. The "non-amyloidogenic" p3 fragment (amyloid β 17-42) is a major constituent of Down syndrome cerebellar preamyloid. *Journal of Biological Chemistry*, 271: 33623-33631, 1996.
 50. Palha JA, Moreira P, **Wisniewski T**, Frangione B, Saraiva MJ. C for T substitution at codon 108: the first identified silent mutation in the transthyretin gene. *Amyloid: International Journal of Experimental Clinical Investigation*, 4:52-53, 1997.
 51. Ghiso J, Calero M, Matsubara E, Governale S, Chuba J, Beavis R, **Wisniewski T**, Frangione B. Alzheimer's soluble amyloid β is a normal component of human urine. *FEBS Letters*, 408: 105-108, 1997.
 52. **Wisniewski T**, Dowjat W, Permanne B, Palha J, Kumar A, Gallo G, Frangione B.

11/26/2014

Thomas Wisniewski MD

Presenilin is associated with Alzheimer's disease amyloid. *American Journal of Pathology*, 151: 601-610, 1997.

53. Permanne B, Perez C, Soto C, Frangione B, **Wisniewski T**. Detection of apolipoprotein E/dimeric soluble amyloid β complexes in Alzheimer's disease brain supernatants. *Biochem. Biophys. Res. Commun.*, 240: 715-720, 1997.
54. **Wisniewski T**, Dowjat WK, Buxbaum JD, Khorhova O, Efthimiopoulos S, Kulczycki J, Lojkowska W, Wegiel J, Wisniewski HM, Frangione B. A novel Polish presenilin-1 mutation (P117L) is associated with familial Alzheimer's disease and leads to death as early as the age of 28 years. *NeuroReport*, 9: 217-221, 1998.
55. K.E. Wisniewski, N.Zhong, W. Kaszmarski, A. Kaszmarski, E. Kida, W.T. Brown, K.O. Schwartz, E.S. Stenroos, A.M. Lazzarini, A.J. Rubin, W.G. Johnson, **T.M. Wisniewski**. Compound heterozygous genotype is associated with protracted juvenile neuronal ceroid lipofuscinosis. *Annals of Neurology*, 43: 106-110, 1998.
56. Askanas V, King Engel W, Chih-Chao Y, Alvarez R B, Lee VMY, **Wisniewski T**. Light and electron microscopic immunolocalization of presenilin I in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal recessive inclusion body myopathy. *American Journal of Pathology*, 152: 889-895, 1998.
57. **Wisniewski T**, Goldman JE. α B-Crystallin is associated with intermediate filaments in astrocytoma cells. *Neurochemistry Research*, 23: 389-396, 1998.
58. Wegiel J, Wisniewski HM, Izabela K, Michal T, Eulalia B, Eirene P, Jerzy K, Wieslaw D, **Wisniewski T**. Cell-type specific enhancement of amyloid β deposition in a novel presenilin-1 mutation (P117L). *Journal of Neuropathology and Experimental Neurology*, 57: 831-838, 1998.
59. Pomara N, Shao B, **Wisniewski T**, Mehta PD. Decreases in plasma A β 1-40 levels with aging in non-demented elderly with apoE-epsilon 4 allele. *Neurochemistry Research*, 23: 1563-1566, 1998.
60. Efthimiopoulos S, Floor E, Georgakopoulos A, Shior J, Cui W, Yasothornsrikul S, Hook VYH, **Wisniewski T**, Buee L, Robakis NK. Enrichment of Presenilin 1 peptides in neuronal large dense core and somatodendritic clathrin coated vesicles. *Journal of Neurochemistry*, 71: 2365-2372, 1998.
61. Copp RP, **Wisniewski T**, Hentati F, Larnaout A, Hamida MB, Kayden HJ. Localization of α -tocopherol transfer protein in the brains of patients with ataxia with vitamin E deficiency and other oxidative stress related neurodegenerative disorders. *Brain*

11/26/2014

Thomas Wisniewski MD

Research, 822: 80-87, 1999.

62. Aucouturier P, Kascak RJ, Frangione B, **Wisniewski T**. Biochemical and conformational variability of human prion strains in sporadic Creutzfeldt-Jakob disease. *Neuroscience Letters*, 274(1):33-36, 1999.
63. Dowjat WK, **Wisniewski T**, Efthimiopoulos S, Wisniewski HM. Inhibition of neurite outgrowth by Familial Alzheimer's disease linked presenilin-1 mutations. *Neuroscience Letters*, 267: 141-144, 1999.
64. Stoltner, SE, Grenfell TJ, Mori C, Wisniewski KE, **Wisniewski TM**, Selkoe DJ, Lemere CA. Temporal accrual of complement proteins in amyloid plaques in Down syndrome with Alzheimer's disease. *American Journal of Pathology*, 156: 489-499, 2000.
65. Soto C, Kascak RJ, Saborio GP, Aucouturier P, **Wisniewski T**, Prelli F, Kascak R, Mendez E, Kumar A, Harris DA, Ironside J, Tagliavini F, Carp RI, Frangione B. Reversion of prion protein conformational changes by synthetic β -sheet breaker peptides. *The Lancet*, 355: 192-197, 2000.
66. Sigurdsson EM, Permanne B, Soto C, **Wisniewski T**, Frangione B. In Vivo Reversal of Amyloid β Lesions in Rat Brain, *Journal of Neuropathology and Experimental Neurology*, 59: 11-17, 2000.
67. Golabek AA, Kida E, Walus M, Perez C, **Wisniewski T**, Soto C. Sodium dodecyl sulphate-resistant complexes of Alzheimer's amyloid β -peptide with the N-terminal, receptor binding domain of apolipoprotein E. *Biophysical Journal*, 79: 1008-1015, 2000.
68. Ji Y, Permanne B, Sigurdsson EM, Holtzman DM, **Wisniewski T**. Amyloid β 40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. *Journal of Alzheimer's Disease*, 3: 23-30, 2001.
69. Poeggeler, B, Miravalle, L, Zagorski M, **Wisniewski T**, Chyan YJ, Zhang Y, Shao H, Bryant-Thomas T, Vidal R, Frangione B, Ghiso J, Pappolla MA. Melatonin reverses the pro-fibrillogenic effects of apolipoprotein E4 on the Alzheimer's β -amyloid protein. *Biochemistry*, 40: 14995-15001, 2001.
70. Dowjat WK, Wisniewski H, **Wisniewski T**. Alzheimer's disease presenilin-1 expression modulates the assembly of neurofilaments. *Neuroscience*, 103: 1-8, 2001.

11/26/2014

Thomas Wisniewski MD

71. Kulczycki J, Bertrand E, Lojkowska W, Dowjat W, **Wisniewski T**, Lyxzywek-Zwierz M. Familial Alzheimer's disease connected with a mutation in presenilin gene 1. *Neurologia I Neurochirurgia Polska*, 35: 213-224, 2001.
72. Aucouturier P, Geissmann F, Saborio G, Meeker HC, Damotte D, Kascsak R, Kascsak R, Carp RI, **Wisniewski T**. Scrapie neuroinvasion in RAG-1^{0/0} mice by transfer of infected splenic dendritic cells. *Journal of Clinical Investigation*, 108: 703-708, 2001.
73. Wegiel J, Bobinski M, Tarnawski M, Dziwiatowski J, Popovitch E, Miller DC, **Wisniewski T**, Golomb J, de Leon MJ, Reisberg B. Fibrillar amyloid- β affects neurofibrillary changes but only in neurons already involved in neurofibrillary degeneration. *Acta Neuropathology* 101: 585-590, 2001.
74. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, **Wisniewski T**. Immunization with a non-toxic/non-fibrillar amyloid- β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. *American Journal of Pathology*, 159: 439-447, 2001.
75. Wen PH, Shao X, Shao Z, Hof PR, **Wisniewski T**, Kelley K, Friedrich VL, Ho L, Painetti GM, Robakis NK, Elder GA. Overexpression of wild type but not an FAD mutant presenilin-1 promotes hippocampal neurogenesis in adult mice, *Neurobiology of Disease*, 10: 8-19, 2002.
76. Mori C, Spooner ET, Wisniewski KE, **Wisniewski TM**, Yamaguchi H, Saido TC, Li C, Tolan DR, Selkoe DJ, Lemere CA. Intraneuronal A β 42 accumulation in Down syndrome brain. *Amyloid*, 9:88-102, 2002.
77. Wang ZH, Ji Y, Zeng B, Raksadawan N, Pastores GM, Ong E, **Wisniewski T**, Kolodny EH. Therapeutic effects of astrocytes expressing both tyrosine hydroxylase and brain-derived neurotrophic factor on a rat model with Parkinson's disease. *Neuroscience*, 113: 629-640, 2002.
78. Mackic JB, Bading J, Ghiso J, Walker L, **Wisniewski T**, Frangione B, Zlokovic BV. Transport across the blood-brain barrier and differential cerebrovascular sequestration of circulating Alzheimer's amyloid- β peptide in aged Rhesus vs. aged Squirrel monkeys. *Vascular Pharmacology*, 38: 303-313, 2002.
79. Poduslo JF, Wengenack TM, Curran GL, **Wisniewski T**, Sigurdsson E, Macura SI, Borowski BJ, Jack CR. Molecular contrast enhanced magnetic resonance imaging of Alzheimer's amyloid plaques. *Neurobiology of Disease*, 11: 315-329, 2002.

11/26/2014

Thomas Wisniewski MD

80. De Leon MJ, Segal S, Tarshish C, DeSanti S, Zinkowski R, Mehta PD, Convit A, Caraos C, Rusinek H, Tsui W, Saint Louis LA, DeBarnardis J, Kerkmanand D, Qadri F, Gary A, Lesbre, **Wisniewski T**, Poirier J, Davies P. Longitudinal Tau levels increase in mild cognitive impairment. *Neuroscience Letters*, 333: 183-186, 2002.
81. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, Wen P, Efthimiopoulos S, **Wisniewski T**, Robakis NK. A presenilin-1 mediated γ -secretase activity cleaves cadherins and controls disassembly of adherens junctions. *EMBO Journal*, 21: 1948-1956, 2002.
82. Wegiel J, Kuchna I, **Wisniewski T**, de Leon MJ, Reisberg B, Pirttila T, Kivimaki T, Lehtimaki. Vascular fibrosis and calcification in the hippocampus in aging, Alzheimer's disease and Down syndrome. *Acta Neuropathologica*, 103: 333-343, 2002.
83. Sigurdsson E, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp R, Meeker HC, Frangione B, **Wisniewski T**. Vaccination delays the onset of prion disease in mice. *American Journal of Pathology*, 161: 13-17, 2002.
84. Wong BS, Li R, Sassoon J, Liu T, Pan T, Kang SC, **Wisniewski T**, Brown DR, Sy MS. Mapping the antigenicity of copper-treated cellular prion protein with the scrapie isoform. *Cellular and Molecular Life Sciences*, 60: 1224-1234, 2003.
85. Sigurdsson EM, Sy MS, Li R, Scholtzova H, Kascsak RJ, Kascsak R, Carp RI, Meeker HC, Frangione B, **Wisniewski T**. Anti-PrP antibodies for prophylaxis following prion exposure. *Neuroscience Letters*, 336: 185-187, 2003.
86. Zaim Wadghiri Y, Sigurdsson EM, Sadowski M, Elliot JI, Li Y, Scholtzova H, Tang CY, Aguinaldo G, Pappolla M, Duff K, **Wisniewski T***, Turnbull DH* (*joint senior authors). Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance micro-imaging. *Magnetic Resonance in Medicine*, 50: 293-302, 2003.
87. Ji Y, Gong Y, Gan W, Beach T, Holtzman DM, **Wisniewski T**. Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients. *Neuroscience*, 122: 305-315, 2003.
88. Sadowski M, Tang CY, Aguinaldo G, Carp R, Meeker HC, **Wisniewski T**. *In vivo* magnetic resonance imaging signal changes in scrapie infected mice. *Neuroscience Letters*, 345: 1-4, 2003.
89. Sigurdsson EM, Brown D, Alim MA, Scholtzova H, Carp R, Meeker HC, Prelli F,

11/26/2014

Thomas Wisniewski MD

- Frangione B, **Wisniewski T**. Copper chelation delays the onset of prion disease. *Journal of Biological Chemistry*, 278: 46199-46202, 2003.
90. Kang SC, Brown DR, Whiteman M, Li R, Pan T, Perry G, **Wisniewski T**, Sy MS, Wong BS. Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie infected mice. *Journal of Pathology*, 203: 603-608, 2004.
 91. Pan T, Li R, Kang SC, Wong BS, **Wisniewski T**, Sy MS. Epitope scanning reveals gain and loss of strain specific antibody binding epitopes associated with the conversion of normal cellular prion to scarpie prion. *Journal of Neurochemistry*, 90: 1205-1217, 2004.
 92. Wegiel J, Kuchna I, Novicki K, Dowjat K, Reisberg B, DeLeon M, **Wisniewski T**, Chen-Hwang MC, Hwang YW. Cell type and brain structure specific patterns of distribution of minibrain kinase in human brain. *Brain Research*, 1010: 69-80, 2004.
 93. Dowjat WK, Kuchna I, **Wisniewski T**, Wegiel J. A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (P117S): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations. *Journal of Alzheimer's Disease*, 6: 31-43, 2004
 94. Sadowski M, Pankiewicz J, Scholtzova H, Ji Y, Quartermain D, Jensen C, Duff K, Nixon RA, Gruen RJ, **Wisniewski T**. Decreased hippocampal glucose metabolism correlates with neuronal loss and impaired recall in Alzheimer's disease model mice. *Journal of Neuropathology and Experimental Neurology*, 63: 418-428, 2004.
 95. Sadowski M, Pankiewicz J, Scholtzova H, Li Y, Quartermain D, Duff K, **Wisniewski T**. Links between the pathology of Alzheimer's disease and vascular dementia. *Neurochemical Research*, 29: 1251-1260, 2004.
 96. Helpern JA, Falangola MF, Dyakin VV, Lee SP, Bogart A, Estok K, Ardekani B, Duff K, Branch C, **Wisniewski T**, De Leon MJ, Wolf O, O'Shea J, Wegiel J, Nixon RA. Magnetic resonance imaging assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. *Magnetic Resonance in Medicine*, 51: 794-798, 2004.
 97. Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, Mathews PM, Fryer JD, Holtzman DM, Sigurdsson EM, **Wisniewski T**. Blocking the apolipoprotein E/ β -amyloid interaction reduces β -amyloid toxicity and decreases β -amyloid load in transgenic mice. *American Journal of Pathology*, 165: 937-948,

11/26/2014

Thomas Wisniewski MD

2004.

98. Sigurdsson EM, Knudsen E, Asuni A, Sage D, Goni F, Quartermain D, Frangione B, **Wisniewski T**. Enhanced cognition with a reduced immune response in an AD mouse model immunized with A β derivatives. *Journal of Neuroscience*, 24: 6277-6282, 2004.
99. Sadowski M, Pankiewicz J, Scholtzova H, Tsai J, Li Y, Carp RI, Meeker HC, Gambetti P, Debnath M, Mathis CA, Li S, Gan WB, Klunk WE, **Wisniewski T**. Targeting prion amyloid deposits in vivo using methoxy-X04, *Journal of Neuropathology and Experimental Neurology*, 63: 775-784, 2004.
100. Pan T, Wong P, Chang B, Li C, Li R, Kang SC, **Wisniewski T**, Sy MS. Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease. *Journal of Virology*, 79: 934-943, 2005
101. Goni F, Knudsen E, Schreiber F, Scholtzova H, Pankiewicz J, Carp R, Meeker HC, Rubenstein R, Brown DR, Chabalgoity JA, Sigurdsson EM, **Wisniewski T**. Mucosal vaccination delays or prevents prion infection via an oral route. *Neuroscience*, 133: 413-421, 2005.
102. Pan T, Chang B, Wong P, Li C, Li R, Kang SC, Thompsett AR, Po T, Yin S, Barnard G, McConnell I, Brown DR, **Wisniewski T**, Sy MS. An aggregate specific ELISA: Detection of conformational differences between recombinant PrP protein dimers and PrP^{Sc} aggregates. *Journal of Virology*, 79: 12355-12364., 2005.
103. Pankiewicz J, Prelli F, Sy MS, Kascsak RJ, Kascsak RB, Spinner DS, Carp RI, Meeker HC, Sadowski M, **Wisniewski T**. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. *European Journal of Neuroscience*, 23: 2635-2647, 2006.
104. Leal MC, Dorfman VB, Gamba GF, Frangione B, **Wisniewski T**, Castano EM, Sigurdsson EM, Morelli L. Plaque-Associated Overexpression of Insulin-Degrading Enzyme in the Cerebral Cortex of Aged Transgenic Tg2576 Mice With Alzheimer Pathology. *Journal of Neuropathology and Experimental Neurology*, 65: :976-987, 2006.
105. Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Wen P, Quartermain D, **Wisniewski T**. Blocking the Apolipoprotein E/Amyloid- β Interaction as a Potential Therapeutic Approach for Alzheimer's Disease. *Proceedings of the National Academy of Science*, 49: 18787-18792, 2006.

11/26/2014

Thomas Wisniewski MD

106. Asuni A, Boutajangout A, Scholtzova H, Knudsen E, Li Y, Quartermain D, Frangione B, **Wisniewski T**, Sigurdsson EM. A β derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice. *European Journal of Neuroscience*, 24: 2530-2542, 2006.
107. Chang B, Cheng X, Yin S, Pan T, Zhang H, Wong P, Kang SC, Xiao F, Yan H, Li C, Wolfe LL, Miller MW, **Wisniewski T**, Greene MI, Sy MS. A blood test for prion: disease associated prion aggregates detected in the blood of infected but asymptomatic animals. *Clinical and Vaccine Immunology*, 14: 36-43, 2007
108. Spinner DS, Kascsak RB, LaFauci G, Meeker HC, Xuemin Y, Flory MJ, Kim JI, Schuller-Levis GB, Levis WR, **Wisniewski T**, Carp RI, Kascsak RJ. CpG Oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrP^{Sc} in mice immunized with 139A scrapie-associated fibrils. *Journal of Leukocyte Biology*, 14(1):36-43, 2007
109. Wegiel J, Kuchna I, Nowicki K, Frackowiak J, Mazur-Kolecka B, Imaki H, Wegiel J, Mehta PD, Silverman WP, Reisberg B, deLeon M, **Wisniewski T**, Pirttilla T, Frey H, Lehtimäki T, Kivimäki T, Visser FE, Kamphorst W, Potempska A, Bolton D, Currie JR, and Miller DL. Intraneuronal A β immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. *Acta Neuropathologica (Berl)*, 113(4):389-402, 2007
110. Litterst C, Georgakopoulos A, Shioi J, Ghersi E, **Wisniewski T**, Wang R, Ludwig A, Robakis NK. Ligand binding and calcium influx induce distinct ectodomain/gamma -secretase processing pathways of EPHB2 receptor. *Journal of Biological Chemistry* 282(22):16155-63, 2007.
111. Webb S, Lekishvili T, Loeschner C, Sellarajah S, Prelli F, **Wisniewski T**, Gilbert IM, Brown DR. Mechanistic insights into prion curing by novel anti-prion compounds. *Journal of Virology*, 81: 10729-10741, 2007.
112. Li Q, Min J, Namm J, Kim EM, Ji Y, Wu H, **Wisniewski T**, Chang YT. Styryl based in vivo imaging agents for β -amyloid plaques. *ChemBioChem*, 8(14): 1679-1687, 2007.
113. Gambetti P, Dong Z, Yuan J, Xiao X, Zheng M, Alsheklee A, Castellani R, Cohen M, Marder K, Harris C, Montine T, **Wisniewski T**, Dickson DW, Hulette CM, DeArmond SJ, Mastrianni JA, Kong Q, Zou WQ. A novel human prion disease with protease-sensitive prion. *Annals of Neurology*, 63: 697-708, 2008.

11/26/2014

Thomas Wisniewski MD

114. Klybin I, Betts V, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Welzel A, Peng Y, **Wisniewski T**, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ. A β dimer-containing human cerebrospinal fluid disrupts synaptic plasticity: prevention by systemic passive immunization. *Journal of Neuroscience*, 28: 4231-4237, 2008.
115. Firuzi O, Zhuo J, Chinnici CM, **Wisniewski T**, Pratico D. 5-lipoxygenase gene disruption reduces amyloid- β pathology in a mouse model of Alzheimer's disease. *FASEB Journal*, 22: 1169-1178, 2008.
116. Sigurdsson EM, Wadghiri YZ, Mosconi L, Blind JA, Knudsen E, Asuni A, Tsui WH, Sadowski M, Turnbull DH, de Leon M, **Wisniewski T**. A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. *Neurobiology of Aging*, 29: 836-847, 2008.
117. Goni F, Chabalgoity JA, Prelli F, Schreiber F, Scholtzova H, Chung E, Kascsak R, Kascsak R, Brown DR, Sigurdsson EM, **Wisniewski T**. High titers of mucosal and systemic anti-PrP antibodies abrogates oral prion infection in mucosal vaccinated mice. *Neuroscience*, 153: 679-686, 2008.
118. Cercy SP, Sadowski MJ, **Wisniewski T**. Prominent neuroleptic sensitivity in a case of early-onset Alzheimer's disease due to Presenilin-1 G206A mutation. *Cognitive and Behavioral Neurology*, 21(3):190-195, 2008.
119. Spinner DS, Cho IS, Park SY, Kim JI, Meeker HC, Ye X, LaFauci G, Kerr DJ, Flory MJ, Kim BS, Kascsak RB, **Wisniewski T**, Levis WR, Schuller-Levis GB, Carp RI, Park E, Kascsak RJ. Accelerated prion disease pathogenesis in the absence of Toll-like receptor 4 (TLR4) signaling. *Journal of Virology*, 82(21):10701-10708, 2008.
120. Wegiel J, Dowjat K, Kaczmarek W, Kuchna I, Nowicki K, Frackowiak J, Mazur Koleccka B, Wegiel J, Silverman WP, Reisberg B, DeLeon M, **Wisniewski T**, Gong CX, Liu F, Adayev T, Chen-Hwang MC, Hwang YW. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. *Acta Neuropathology*, 116(4):391-407, 2008.
121. H. Scholtzova, Y. Z. Wadghiri, M. Douadi, E. M. Sigurdsson, Y. Li, D. Quartermain, P. Banerjee, and **T. Wisniewski**. A NMDA receptor antagonist leads to behavioral improvement and amyloid reduction in Alzheimer's disease model transgenic mice shown by micro-magnetic resonance imaging. *Journal of Neuroscience Research*, 86 (12):2784-2791, 2008.

11/26/2014

Thomas Wisniewski MD

122. Trouche SG, Asuni A, Rouland S, **Wisniewski T**, Frangione B, Verdier JM, Sigurdsson EM, Mestre-Frances N. Antibody response and plasma A β 1-40 in young *Microcebus Murinus* primates immunized with A β 1-42 and its derivatives. *Vaccine*, 27:957-964, 2009.
123. Zhan J, Brys M, Glodzik L, Tsui W, Javier E, Wegiel J, Kuchna I, Pirraglia E, Li Y, Mosconi L, Saint Louis LA, Switalski R, De Santi S, Kim BC, **Wisniewski T**, Reisberg B, Bobinski M, de Leon MJ. An entorhinal cortex sulcal pattern is associated with Alzheimer's disease. *Human Brain Mapping*, 30: 874-882, 2009.
124. Boutajangout A, Goni F, Knudsen E, Schreiber F, Asuni A, Quartermain D, Frangione B, Chabalgoity A, **Wisniewski T**, Sigurdsson EM. Diminished amyloid β burden in Tg2576 mice following a prophylactic oral immunization with a Salmonella based amyloid β derivative vaccine. *Journal of Alzheimer's Disease*, 18: 961-972, 2009.
125. Sadowski MJ, Pankiewicz J, Prelli F, Scholtzova H, Spinner DS, Kascsak RB, Kascsak RJ, **Wisniewski T**. Anti-PrP Mab 6D11 suppresses PrP^{Sc} replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. *Neurobiology of Disease*, 34: 267-278, 2009.
126. Mosconi, L.; Mistur, R.; Switalski, R.; Tsui, W.H.; Glodzik, L.; Li, Y.; Pirraglia, E.; De, Santi S.; Reisberg, B.; **Wisniewski, T.**; De Leon, M.J. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. *European Journal of Nuclear Medicine and Molecular Imaging*, 36(5): 811-822, 2009.
This manuscript won the "Best Clinical Paper of 2009" award from Springer and the European Association of Nuclear Medicine.
127. Scholtzova H, Kascsak RJ, Bates KA, Boutajangout A, Kerr DJ, Meeker HC, Mehta PD, Spinner DS, **Wisniewski T**. Induction of Toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease related pathology, *Journal of Neuroscience*, 29: 1846-1854, 2009.
128. Wegiel J, Kuchna I, Nowicki K, Imaki H, Wegiel J, Marchi E, Ma SY, Chauhan A, Chauhan V, Bobrowicz TW, de Leon M, Louis LA, Cohen IL, London E, Brown WT, **Wisniewski T**. The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes, *Acta Neuropathol.*, 119: 755-770, 2010.
129. Zhang W, Li YS, Nardi MA, Dang S, Yang J, Li Z, Karpatkin S, **Wisniewski T**. Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet

11/26/2014

Thomas Wisniewski MD

- GPIIIa49-66 ligand which specifically targets the platelet thrombus, *Blood*, 116: 2336-2344, 2010.
130. Goni F, Prelli F, Ji Y, Scholtzova H, Yang J, Sun Y, Liang FX, Kascsak R, Kascsak R, Mehta P, **Wisniewski T**. Immunomodulation Targeting Abnormal Protein Conformation Reduces Pathology in a Mouse Model of Alzheimer's Disease. *PLoS ONE*, 5(10): e13391, 2010.
 131. Chung E, Ji Y, Sun Y, Kascsak R, Kascsak R, Mehta P, Strittmatter SM, **Wisniewski T**. Anti-PrP^C monoclonal antibody infusion as a novel treatment for A β oligomer cognitive deficits. *BMC Neuroscience*, 11:130, 2010.
 132. Wegiel J, Kaczmarek W, Barua M, Kuchna I, Nowicki K, Wang KC, Wegiel J, Yang S, Frackowiak J, Mazur-Kolecka B, Silverman WP, Reisberg B, Monteiro I, de Leon M, **Wisniewski T**, Dalton A, Lai F, Hwang YW, Adayev T, Liu F, Iqbal K, Iqbal IG, Gong CX. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome. *Journal of Neuropathology and Experimental Neurology*, 70(1):36-50, 2011.
 133. Yang J, Ji Y, Mehta P, Bates KA, Sun Y, **Wisniewski T**. Blocking the apolipoprotein E/amyloid β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. *Journal of Alzheimer's Disease*, 24(2):269-285, 2011.
 134. Yang J, Zaim Wadghiri Y, Hoang DM, Tsui W, Sun Y, Chung E, Li Y, Wang A, de Leon M, **Wisniewski T**. Detection of amyloid plaques targeted by USPIO-A β 1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. *Neuroimage*, 55: 1600-1609, 2011.
 135. Dang S, Hong T, **Wisniewski T**, Zhang W. A novel strategy of dissolution of pre-existing platelet thrombus by synergistic administration of a low concentration of bifunctional antibodies against beta3 integrin. *PLoS ONE*, 6(10): e27012, 2011.
 136. Chung E, Prelli F, Dealler S, Lee WS, Chang YT, **Wisniewski T**. Styryl-based and Tricyclic Compounds as Potential Anti-Prion Agents. *PLoS ONE*, 6(9): e24844, 2011 (<http://dx.plos.org/10.1371/journal.pone.0024844>)
 137. Leal MC, Surace EI, Holgado MP, Ferrari CC Tarelli R, Pitossi F, **Wisniewski T**, Castano EM, Morelli L. Notch signaling proteins HES-1 and Hey-1 bind to insulin degrading enzyme (IDE) proximal promoter and repress its transcription

11/26/2014

Thomas Wisniewski MD

and activity: implications for cellular A β metabolism. *BBA-Molecular Cell Research*, 1823(2): 227-235, 2012.

138. Pomara N, Bruno D, Sarreal AS, Hernando RT, Nierenberg J, Petkova E, Sidtis JJ, **Wisniewski T**, Mehta PD, Pratico D, Zetterberg H, Blennow K. Cerebrospinal fluid amyloid beta levels are lower and F2-isoprostanes higher in individuals with major depressive disorder. *American Journal of Psychiatry*, 169(5):523-30, 2012.
139. Wegiel J, Schanen NC, Cook EH, Sigman M, Brown WT, Kuchna I, Nowicki K, Wegiel J, Imaki H, Ma SY, Marchi E, Wierzba-Bobrowicz T, Chauhan A, Chauhan V, Cohen IL, London E, Flory M, Lach B, **Wisniewski T**. Differences between the patterns of developmental abnormalities in autism associated with duplications 15q11.2q13 and idiopathic autism. *Journal of Neuropathology and Experiment Neurology*, 71(5):382-397, 2012.
140. Chang B, Petersen R, **Wisniewski T**, Rubenstein R. Influence of Mabs on PrP^{Sc} formation using *in vitro* and cell-free systems. *PloS ONE*, 7(7): e41626, 2012.
141. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Takahashi H, Vortmeyer A, **Wisniewski T**, Gunther EC, Strittmatter SM. Alzheimer amyloid- β oligomer bound to post-synaptic prion protein signals via Fyn to alter NMDA receptors, dendritic spines and seizures. *Nature Neuroscience*, 15(9): 1227-1235, 2012.
142. Zhang W, Dang S, Hong T, Tang J, Fan J, Bu D, **Wisniewski T**. A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment. *Blood*, 120(14): 2889-2898, 2012.
143. Wegiel J, Frackowiak J, Kolecka BM, Schanen NC, Cook Jr EH, Sigman M, Brown WT, Kuchna I, Wegiel J, Nowicki K, Imaki H, Ma SY, Chauhan A, Chauhan V, Miller DL, Mehta PD, Cohen IL, London E, Reisberg B, de Leon MJ, **Wisniewski T**. Abnormal Intracellular Accumulation and Extracellular A β Deposition in Idiopathic and Dup 15 Autism. *PLoS ONE*, 7(5):e35414, 2012.
144. **Wisniewski T**, Newman K, Javitt NB. Alzheimer's disease: focus on desmosterol. *Journal of Alzheimer's Disease*, 33: 881-888, 2013.
145. Wadghiri YZ, Li J, Wang J, Hoang DM, Sun Y, Xu H, Tsui W, Li Y, Wang A, de Leon M, **Wisniewski T**. Detection of Amyloid Plaques Targeted by Bifunctional USPIO in Alzheimer's Disease Transgenic Mice using Magnetic Resonance Microimaging. *PLoS ONE*, 8(2):e57097, 2013.

11/26/2014

Thomas Wisniewski MD

146. Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, **Wisniewski T**, Guthrie EC, Koleske J, Nygaard HB, Strittmatter SM. Metabotropic Glutamate Receptor 5 Mediates Signaling from Alzheimer A β Oligomer Bound to Prion Protein, *Neuron*, 79(5): 887-902, 2013.
147. Ji Y, Liu M, Huo YR, Liu S, Shi Z, Liu S, **Wisniewski T**, Wang J. Apolipoprotein E4 frequency is increased among frontotemporal dementia and Alzheimer's disease patients in a Chinese population. *Dementia and Geriatric Cognitive Disorders*, 36: 163-170, 2013.
148. Rubenstein R, Chiu A, Chang B, **Wisniewski T**. Influence of CD40 on Prion Disease and the Immune Response to Recombinant PrP. *Journal of Neuroimmunology*, 257 (1-2): 21-27, 2013.
149. Wegiel J, Kuchna I, Nowicki K, Imaki H, Wegiel J, Yong Ma S, Azmitia EC, Banerjee P, Flory M, Cohen IL, London E, Brown TW, Hare KC, **Wisniewski T**. Contribution of olivo-floccular circuitry developmental defects to atypical gaze in autism. *Brain Research*, 1512: 106-122, 2013.
150. Goni F, Herline K, Peyser D, Wong K, Ji Y, Sun Y, Mehta P, **Wisniewski T**. Immunomodulation Targeting Both A β and Tau Pathological Conformers Ameliorates Alzheimer's Disease Pathology in TgSwDI and 3xTg Mouse Models. *Journal of Neuroinflammation*, 10: 150, 2013.
150. Liu S, Breitbart A, Sun Y, Mehta PD, Boutajangout A, Scholtzova H, **Wisniewski T**. Blocking the Apolipoprotein E/Amyloid β Interaction in Triple Transgenic Mice Ameliorates Alzheimer's Disease Related Amyloid β and Tau Pathology. *Journal of Neurochemistry*, 128: 577-591, 2014.
152. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloskavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators (including **Wisniewski T**) Two phase 3 trials of bapineuzumab in mild to moderate Alzheimer's disease. *New England Journal of Medicine*, 370(4): 322-333, 2014.
153. Iulita MF, Carmo SD, Ower A, Fortress A, Aguilar LF, Hanna M, **Wisniewski T**, Granholm AC, Buhusi M, Busciglio J, Cuello AC. Nerve Growth Factor Metabolic Dysfunction in Down's Syndrome Brains: a Cause for Cholinergic Degeneration? *Brain*, 137: 860-872, 2014.

11/26/2014

Thomas Wisniewski MD

154. Chung K, Boutajangout A, **Wisniewski T**, Chan J, Stopler T, Vincent N, Batchan M, D'Urso J, Lin Y, Kline R, Kamer A, Stone E, Yaghmoor F, Blanck T, Quartermain D, Bekker A, Haile M. The COX-2 Inhibitor Meloxicam Ameliorates Neuroinflammation and Depressive Behavior in Adult Mice After Splenectomy. *PLoS ONE*, under review.
155. Wegiel J, Flory M, Kuchna I, Nowicki K, Ma SY, Imaki H, Wegiel J, Cohen IL, London E, **Wisniewski T**, Brown WT. Stereological study of the neuronal number and volume of 38 brain subdivisions of subjects diagnosed with autism reveals significant alterations restricted to the striatum, amygdala and cerebellum. *Acta Neuropathologica Communications*, 2: 141, 2014.
156. Wegiel J, Flory M, Kuchna I, Nowicki N, Ma SY, Imaki H, Wegiel J, Cohen IL, London E, Brown WT, **Wisniewski T**. Brain-region-specific alterations of the trajectories of neuronal volume growth throughout the lifespan in autism. *Acta Neuropathologica Communications*, 2: 28, 2014.
157. Zhang Y, Shi Z, Liu M, Liu S, Yue W, Liu S, Xiang L, Lu H, Liu P, **Wisniewski T**, Wang J, Ji Y. Prevalence of cognitive impairment no dementia in a rural area of northern China. *Neuroepidemiology*, 42: 197-203, 2014.
158. Scholtzova H, Chianchiano P, Pan J, Sun Y, Goni F, Mehta PD, **Wisniewski T**. Toll-like receptor 9 stimulation for reduction of amyloid β and tau Alzheimer's disease related pathology. *Acta Neuropathologica Communications*, 2: 101, 2014.
159. Wegiel J, Flory M, Kuchna I, Nowicki K, Ma SY, Imaki H, Wegiel J, Frackowiak J, Kolecka BM, Wierzba-Bobrowicz T, London E, **Wisniewski T**, Brown WT. Neuronal nucleus and cytoplasm volume deficit in autistic children and volume increase in autistic adolescents and adults. *Acta Neuropathologica Communications*, under review.
160. Goñi F, Mathiason CK, Yim L, Wong K, Hayes-Klug J, Nalls A, Peyser D, Estevez V, Xu J, Osborn DA, Miller KV, Warren RJ, Brown DR, Chabalgoity JA, Hoover EA, **Wisniewski T**. Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease. *Vaccine*, in press.
161. Teohb CL, Sua D, Sahua S, Yunb SW, Prelli F, **Wisniewski T**, Chang YT. A Chemical Fluorescent Probe for the Detection of A β Oligomers. *Angew Chem*, under review.
162. Drummond ES, Nayak S, Ueberheide B, **Wisniewski T**. Proteomic analysis of individual

11/26/2014

Thomas Wisniewski MD

neurons isolated from formalin-fixed paraffin-embedded brain sections using laser microdissection. *Nature Methods*, under review

Books, Chapters in Books, Letters and Reviews:

1. Post K, Onesti S, **Wisniewski T**. Pituitary Apoplexy. In Intracranial Hemorrhages: Etiology, Pathogenesis, Clinical Features and Treatment. Editor Kauffman H.

11/26/2014

Thomas Wisniewski MD

Raven Press; 1991

2. **Wisniewski T.M.**, Wisniewski HM. Alzheimer's Disease and the Cerebral Amyloidoses. In Neurodevelopment, Aging and Cognition. Editors Ivica Kostovic, Stevo Knezevic, Henry M. Wisniewski and George J. Spilich, Birkhauser, Boston ; p157-172; 1992.
3. Frangione B, Haltia M, Levy E, Ghiso J, Kiuru S, Prelli F, **Wisniewski T.** Familial amyloidosis- Finnish type- and its relationship to Lewy bodies in Parkinson's and Diffuse Lewy Body disease. In the Proceedings of the XIth International Congress of Neuropathology- Kyoto; p150-156; 1992.
4. **Wisniewski T**, Haltia M, Ghiso J, Frangione B. I corpi di Lewy immunoreagiscono con gli anticorpi dell-amiloide di tip Finnico omologo alla gelsolina. *Update on Parkinson's disease and migraine* 1992; 2:59-60.
6. **Wisniewski T**, Frangione B. Aberrant aggregation of a normal amyloid precursor protein fragment. *Neuroscience Facts* 1992; 3:66.
7. Frangione B, **Wisniewski T**, Tagliavini F, Bugiani O, Ghiso J. Alzheimer's disease and Dutch variant: "Opposing faces of a single coin." In Alzheimer's Disease: Advances in Clinical and Basic Research. Editors: Corain B, Iqbal K, Nicolin M. Wiley; p:387-396;1993.
8. Frangione B, **Wisniewski T**, Ghiso J. Alzheimer's disease and amyloid β . In Amyloid and Amyloidosis 1993. Ed.:Kiselevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID. Parthenon Publishing, 1994; pp:310-315.
9. Ghiso J, **Wisniewski T**, Frangione B. Unifying features of systemic and cerebral amyloidoses. *Molecular Neurobiology* 1994; 8: 49-64.
10. Frangione B, **Wisniewski T**, Ghiso J. Position Paper on Alzheimer's Disease Research. *Neurobiology of Aging* 1994; 15 (suppl 2):S97-S99.
11. Frangione B, **Wisniewski T**, Castano E, Ghiso J. Amyloids, Genes and Chaperones. In Research Advances in Alzheimer's Disease and Related Disorders. Ed. Iqbal K., Mortimer JA, Winblad B, Wisniewski T. Publisher John Wiley, Chapter 61, pp:563-568; 1995.
12. Zlokovic, B., Mackic, J., Martel, C., **Wisniewski, T.**, Frangione, B., and Ghiso, J.: The blood brain barrier regulates transport of Alzheimer's amyloid β and apolipoproteins E and J. In K. Iqbal, J. Mortimer, B. Winblad and H.

11/26/2014

Thomas Wisniewski MD

Wisniewski (eds.) Research advances in Alzheimer's disease and related disorders. Proceedings of the IV international conference on Alzheimer's disease and related disorders. Minneapolis, July/August, 1994. John Wiley & Sons, Chichester (England), 1995, pp 585-595.

13. **Wisniewski T**, Frangione B. The molecular biology of brain aging and neurodegenerative disorders. *Acta Neurobiologiae Experimentalis* 1996; 56: 267-279.
14. **Wisniewski T**, Frangione B. Apolipoprotein E, Amyloidosis and Alzheimer's Disease. *Dementia (Japan)* 1996; 10: 171-183.
15. Frangione B, Castano EM, **Wisniewski T**, Ghiso J, Prelli F, Vidal R. Apolipoprotein E and amyloidosis. *Ciba Foundation Symposium* 1996; 199: 132-141.
16. Frangione B, Castano EM, Prelli F, Soto C, Ghiso J, **Wisniewski T**. Chaperoning Amyloid in Alzheimer's Disease: The Art of Avoiding Sticky Situations? In: A.D.Roses, K.H. Weisgraber and Y.Christen (ed.) Apolipoprotein E and Alzheimer's Disease; Springer-Verlag, Berlin, Heidelberg, 1996; pp: 151-160.
17. **Wisniewski T**, Ghiso J, Frangione B. Alzheimer's Disease and Amyloid β . *Neurobiology of Disease* 1997; 4: 313-328.
18. **Wisniewski T**, Dowjat K, Frangione B. The Prionoses and Other Conformational Disorders. *Amyloid: The International Journal of Experimental and Clinical Investigation* 1998; 5: 212-224.
19. Wisniewski HM, Wegiel J, **Wisniewski T**. Pathogenesis of amyloid- β plaques: activated microglia the cause of fibrillar amyloid formation and neuropil degeneration. *NeuroScience News* 1998; 1: 30-34.
20. Lalowski M, Baumann M, Rauvala H, Frangione B, **Wisniewski T**. HB-GAM, a novel amyloid associated protein, is present in prion related disorders and other cerebral amyloidoses. In: Fischer et al. (Editors) Progress in Alzheimer's and Parkinson's Diseases; Plenum Press, New York, 1998; pp: 121-131.
21. Aucouturier, P, Frangione B, **Wisniewski T**. Prion Diseases and the Immune System. *Annals of Internal Medicine* (Paris, France), 1999; 150: 75-78.
22. **Wisniewski T**, Frangione B. Amyloid: Chemical and Molecular Considerations. In: M. DeLeon (Ed.) An Atlas of Alzheimer's Disease. Parthenon Publishing, Carnforth,

11/26/2014

Thomas Wisniewski MD

U.K., 1999; pp:109-130.

23. Aucouturier P, Carp RI, Carnuad C, **Wisniewski T**. Prion Disease and the Immune System. *Clinical Immunology*, 2000, 96: 79-85.
24. **Wisniewski T**, Frangione B. Book Review of *Prion Biology and Diseases*, Edited by Stanley B. Prusiner. *New England Journal of Medicine*, 2000, 342:983.
25. Kayden HJ, **Wisniewski T**. On the biological activity of Vitamin E. *American Journal of Clinical Nutrition*, 2000, 72: 201-202.
26. **Wisniewski T**. Henry M. Wisniewski, A life history. *Journal of Alzheimer's Disease*, 2001, 3: 7-22.
27. **Wisniewski T**, Sigurdsson EM, Aucouturier P, Frangione B. Chapter 13: Conformation as a Therapeutic Target in the Prionoses and other Neurodegenerative Conditions. In Baker HF (ed.) Molecular and Cellular Pathology in Prion Diseases. The Humana Press, Inc.(Totowa, NJ) p: 223-236, 2001.
28. **Wisniewski T**. Prion Related Diseases. In Lorenzo NY (ed.) eMedicine Neurology. <http://www.emedicine.com/neuro/topic662.htm>, 2002
29. Sigurdsson EM, Frangione B, **Wisniewski T**. A safer vaccine for Alzheimer's disease? *Neurobiology of Aging*, 23: 1001-1008, 2002.
30. **Wisniewski T**, Brown D, Sigurdsson EM. Therapeutics in Alzheimer's and Prion Diseases. *Biochemical Society Transactions*, 30: 574-578, 2002.
31. Sigurdsson EM, Frangione B, **Wisniewski T**. Immunization for Alzheimer's Disease. *Drug Development Research*, 56: 135-142, 2002.
32. Sigurdsson EM, **Wisniewski T**, Frangione B. Infectivity of Amyloid Diseases. *Trends in Molecular Medicine*, 8: 411-413, 2002.
33. **Wisniewski T**, Sigurdsson EM. Immunization Treatment Approaches in Alzheimer and Prion Diseases. *Current Neurology and Neuroscience Reports*, 2: 400-404, 2002.
34. Wegiel J, **Wisniewski T**, Reisberg B, Silverman W. Alzheimer dementia neuropathology. In: Dementia. Presentations, differential diagnosis, and nosology. Edited by V. Olga B. Emery, PhD. and Thomas E. Oxman, MD., The Johns Hopkins University Press, Baltimore and London, Chapter 4: 89-120, 2003.

11/26/2014

Thomas Wisniewski MD

35. Sadowski M, **Wisniewski T**. Immunological treatment and imaging approaches for prion disease. *Current Medical Chemistry: Immunology, Endocrine & Metabolic Agents*, 3: 113-118, 2003.
36. Sadowski M, Verma A, **Wisniewski T**. Prion Diseases. In Neurology in Clinical Practice, 4th Edition, Bradley W. (ed.), Chapter 59G: 1613-1630, 2004.
37. Sigurdsson EM, Wadghiri YZ, Sadowski M, Elliot JI, Li Y, Scholtzova H, Tang CY, Aguinaldo G, Duff K, Turnbull DH, **Wisniewski T**. In vivo magnetic resonance of amyloid plaques in Alzheimer's disease model mice. Chapter in: *The Living Brain and Alzheimer's Disease*, Fondation IPSEN. Pages: 47-59, Ed. Hyman B., Springer Verlag Berlin Heidelberg, 2004.
38. **Wisniewski T**, Sadowski M. Book title: 100 Questions and Answers about Alzheimer's disease. Jones and Bartlett Publishers, 2004.
39. Sadowski M, **Wisniewski T**. Vaccines for Conformational Disorders. *Expert Review of Vaccines*, 3 (3): 279-290, 2004.
40. **Wisniewski T**. Mad cow disease and variant Creutzfeldt-Jakob disease. In Lorenzo NY (ed.) eMedicine Neurology. <http://www.emedicine.com/neuro> , 2004.
41. Ghiso J, **Wisniewski T**. An animal model of vascular amyloidosis. *Nature Neuroscience*, 7: 902-904, 2004.
42. Sasson J, Sadowski M, **Wisniewski T**, Brown DR. Therapeutics and prion disease: can immunization or drugs be effective? *Mini-Reviews in Medicinal Chemistry*, 5: 361-366, 2005.
43. Wadghiri YZ, Sigurdsson EM, **Wisniewski T**, Turnbull DH. MR Imaging of Amyloid Plaques in Transgenic Mice. Chapter 27, pages: 365-380; In Sigurdsson EM (ed) Amyloid Proteins: Methods in Molecular Biology Vol. 299, Humana Press Inc., Totowa, NJ, 2005.
44. **Wisniewski T**, Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer's disease. *Brain Pathology*, 15: 72-77, 2005.
45. **Wisniewski T**. Is amyloid-beta-peptide immunization clinically effective in patients with Alzheimer's disease? *Nature Clinical Practice Neurology*. 1: 84-85, 2005.
46. Sigurdsson E., **Wisniewski T**. Promising Developments in Prion Immunotherapy. *Expert Reviews of Vaccines*, 4: 607-610, 2005.

11/26/2014

Thomas Wisniewski MD

47. **Wisniewski T.**, Sigurdsson E. Prion Related Diseases. In Lorenzo NY (ed.) eMedicine Neurology. <http://www.emedicine.com/neuro/topic662.htm>, 2006
48. Sadowski M, **Wisniewski T.** Apolipoproteins in different amyloidoses. In *Protein Misfolding. Aggregation and Conformational Diseases*. Editors: Uversky VN, Fink AL; Kluwer Academic/Plenum Publishers. Chapter 16, pages: 329-350, 2006.
49. Sadowski M, **Wisniewski T.** Disease modifying approaches for Alzheimer's pathology. *Current Pharmaceutical Design* 13(19):1943-54, 2007.
50. **Wisniewski T**, Chabalgoity J.A. & Goni F. Is vaccination against transmissible spongiform encephalopathy feasible? In *Animal vaccination – Part 1: development, production and use of vaccines* (P.-P. Pastoret, M. Lombard & A.A. Schudel, eds). *Rev. sci. tech. Off. int. Epiz.*, 26 (1), 243-251, 2007.
51. Sigurdsson E., **Wisniewski T.** Therapeutic Approaches for Prion and Alzheimer's Diseases. *FEBS Journal*, 274: 3784-3798, 2007.
52. Sadowski M, Verma A, **Wisniewski T.** Infections of the Nervous System: Prion Diseases. In *Neurology in Clinical Practice*, 5th Edition, Bradley W. (ed.), Chapter 57G, 1567-1581, 2008.
53. **Wisniewski T**, Konietzko U. Amyloid- β immunisation for Alzheimer's disease. *Lancet Neurology*, 7(9):805-811, 2008.
54. **Wisniewski T**, Sadowski M. Preventing A β fibrillization and deposition: β -sheet breakers and pathological chaperone inhibitors. *BMC Neuroscience*, 9(Suppl 2):S5, 2008.
55. **Wisniewski T.** AD Vaccines: Conclusions and Future Directions, In *CNS & Neurological Disorders-Drug Targets*, 8(2): 160-166, 2009.
56. **Wisniewski T**, Boutajangout A. Vaccination as a Therapeutic Approach for Alzheimer' Disease. *Mount Sinai Journal of Medicine*, 77: 17-31, 2010.
57. **Wisniewski T**, Boutajangout A. Immunotherapeutic Approaches for Alzheimer's disease in transgenic mouse models. *Brain Structure and Function*, 214: 201-218, 2010.
58. Wegiel J, **Wisniewski T**, Chauhan A, Chauhan V, Kuchna I, Nowicki K, Imaki H, Wegiel J, Ma SY, Bobrowicz T, Cohen I, London E, Brown TW. Type,

11/26/2014

Thomas Wisniewski MD

topography, and sequelae of neuropathological changes: Shaping clinical phenotype of autism. In *Autism: Oxidative stress, inflammation, and immune abnormalities*. Boca Raton, FL, CRC Press, pages: 279-282, 2010.

59. **Wisniewski T**, Sigurdsson EM. Murine Models of Alzheimer's Disease and Their Use in Developing Immunotherapies. *BBA-Molecular Basis of Disease*, 1802: 847-859, 2010.
60. de Leon MJ, Rusinek H, Tsui W, **Wisniewski T**, Wegiel J, George A. Neuroimaging of cognitive disorders: commentary. Chapter 28 in *Understanding Neuropsychiatric Disorders*, Editors: Shenton ME, Turetsky BI. Cambridge University Press, pages: 395-401, 2010.
61. **Wisniewski T**, Goni F. Immunomodulation for Prion and Prion Related Diseases. *Expert Review of Vaccines*, 9(12): 1441-1452, 2010.
62. Wadghiri YZ, Hoang DM, **Wisniewski T**, Sigurdsson EM. In vivo imaging of amyloid plaques in transgenic mice. *Methods in Molecular Biology*, 849: 435-451, 2012.
63. **Wisniewski, T**, Goñi, F. Immunomodulation. In: Zou, W. Q., Gambetti, P. (Eds) *Prions and Diseases*, 1st ed., Volume 2: Animals, Humans and the Environment. Publisher: Springer, New York, Chapter 17: 267-287, 2012.
64. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Davies P, Del Tredici K, Duychaerts C, Frosch MP, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, **Wisniewski T**, Woltjer RL, Beach TG. Correlation of Alzheimer's Disease Neuropathologic Changes and Cognitive Status: a Review of the Literature. *Journal of Neuropathology and Experimental Neurology*, 71(5):362-381, 2012.
65. **Wisniewski T**, Goñi, F. Could Immunomodulation be used to Treat Prion Diseases? *Expert Review of Anti-infective Therapy*, 10(3): 307-317, 2012.
66. Potter H, **Wisniewski T**. Apolipoprotein E: essential catalyst of the Alzheimer amyloid cascade. *International Journal of Alzheimer's Disease*, 2012:489428, 2012.
67. **Wisniewski T**. Active Immunotherapy for Alzheimer's disease. *Lancet Neurology*, 11(7):571-572, 2012.
68. Wegiel J, Schanen NC, Cook EH, Brown WT, Kuchna I, Nowicki K, Wegiel J, Imaki H,

11/26/2014

Thomas Wisniewski MD

- Ma SY, London E, **Wisniewski T**. Clinicopathological stratification of idiopathic autism associated with duplications 15q11.2-q13. In *The Neuroscience of Autism Spectrum Disorders*. Chapter 3.9, pages: 347-359, Edited by Joseph D. Buxbaum & Patrick R. Hof. Academic Press, Elsevier, Amsterdam, 2013
69. Boutajangout A., **Wisniewski T**. The Innate Immune System in Alzheimer's Disease. *International Journal of Cell Biology*, Volume 2013, Article ID 576383, 1-7. 2013.
 70. Willhite CC, Karyakina NA, Yokel RA, Mornoli F, Yenugadhati N, **Wisniewski TM**, Ian MF, Krewski A, Krewski D. Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanodot aluminum, aluminum oxide and the soluble salts. *Critical Reviews in Toxicology*, 44 (S4):1-80, 2014.
 71. Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K, Granholm AC, Iqbal K, Krams M, Lemere C, Lott I, Mobley W, Ness S, Nixon R, Potter H, Reeves R, Sabbagh M, Silverman W, Tycko B, Whitten M, **Wisniewski T**. Down Syndrome and Alzheimer's Disease: Common Pathways, Common Goals. *Alzheimer's & Dementia*, in press.
 72. Wegiel J, Morys J, Kowianski P, Ma SY, Kuchna I, Nowicki K, Imaki H, Wegiel J, Flory M, Brown TW, **Wisniewski T**. Delayed development of the claustrum in autism. In *The Claustrum: Structural, Functional, and Clinical Neuroscience*. Edited by Smythies JR, Edelstein LR, Ramachandran VS. Academic Press, Chapter 8, pages: 225-235, 2014.
 73. Rubenstein R, Peterson R, **Wisniewski T**. "Prion Diagnosis", In the Manual of Molecular and Clinical Laboratory Immunology (8th Edition) published by the American Society for Microbiology Press. (R.L. Hodinka, Ed.), in press.
 74. **Wisniewski T**, Goni F. Immunotherapy for Alzheimer's disease. *Biochemical Pharmacology*, 88: 499-507, 2014.
 75. Sabharwal P, **Wisniewski T**. Novel Immunological Approaches for the Treatment of Alzheimer's disease, *Chinese Journal of Contemporary Neurology and Neurosurgery*, 14: 139-151, 2014.
 76. Boutajangout A, **Wisniewski T**. Tau as a therapeutic target in Alzheimer's disease. *Gerontology*, 60: 381-385, 2014.
 77. Yaghmoor F, Noorsaeed A, Alsaggaf S, Aljohami W, Scholtzova H, Boutajangout A,

11/26/2014

Thomas Wisniewski MD

Wisniewski T. The Role of TREM2 in Alzheimer's Disease and other Neurological Disorders. *Journal of Alzheimer's Disease and Parkinsonism*, 4(5): 160, 2014.

78. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Alafuzoff I, Arnold SE, Attems J, Beach TG, Cairns NJ, Dickson DW, Gearing M, Grinberg L, Hof PR, Hyman BT, Jellinger K, Kovacs GG, Knopman DS, Kofler J, Masliah E, McKee A, Murray ME, Neltner JH, Santa-Maria I, Seeley WW, Serrano-Pozo A, Shelanski ML, Stein T, Takao M, Thal DR, Toledo JB, Troncoso JC, Vonsattel JP, White 3rd CL, **Wisniewski T**, Woltjer RL, Yamada M, and Nelson PT. Primary age-related tauopathy (PART): a common pathology associated with human aging. *Acta Neuropathologica*, 128(6): 755-766. 2014.
79. **Wisniewski T**, Goni F. Immunotherapeutic Approaches for Alzheimer's Disease. *Neuron*, in press.

Total of 241 full length peer reviewed publications (162 peer reviewed original data manuscripts and 79 peer reviewed book chapters, reviews or books).

Average Citations per manuscript: ~21

H-Index: 56 (using Web of Science); 62 (using Google Scholar)

Total Citations: >13,000